BR112020006440B1 - COSMETIC METHOD FOR THE TREATMENT OF HUMAN PERSPIRATION AND COSMETIC COMPOSITION - Google Patents

Abstract

The invention relates to a cosmetic method for treating human perspiration and, optionally, body odors resulting from perspiration, which includes the use of at least one Xn+ cation of valence n, at least one Ym- anion of valence m, and at least a modulating agent.

Description

[001] This invention relates to a cosmetic method for treating human perspiration and, optionally, body odors resulting from perspiration, which includes the use of at least one Xn+ cation of valence n, at least one Ym- anion of valence m and at least one modulating agent.

[002] This invention relates, in particular, to a cosmetic method for treating human perspiration and, optionally, body odors resulting from perspiration, which includes: (i) both mixing shortly before use of at least one composition A and at least one composition B; said compositions A and B being packaged separately, followed by applying the resulting mixture to the surface of the skin; (ii) as applying to the surface of the skin, simultaneously or sequentially, at least one composition A and at least one composition B separately packaged; (iii) or applying to the surface of the skin a composition comprising on the same support at least one composition A and at least one composition B; - said composition A comprising in a cosmetically acceptable medium at least one Xn+ cation of valence n; - said composition B comprising in a cosmetically acceptable medium at least one Ym- anion of valence m; - mixing said composition A with said composition B further comprising at least one modulating agent.

[003] The armpits, as well as other parts of the body, are generally the site of various discomforts that may or may not result directly from perspiration problems. These phenomena often cause unpleasant and uncomfortable sensations, which are mainly due to the presence of sweat resulting from perspiration which can, in certain cases, make the skin damp and clothes wet, in particular, at the level of the armpits or back, as such , leaving visible traces. Furthermore, the presence of sweat can generate the release of body odors, which are often unpleasant. Finally, during its evaporation, sweat can also leave behind salts and/or proteins on the surface of the skin that turn clothes whitish. These discomforts must be taken into account, even in the case of moderate perspiration.

[004] In the field of cosmetics, it is well known to use a topical application of antiperspirant products containing substances that have the effect of limiting and even suppressing the flow of sweat, in order to solve the problems mentioned previously in the present application. These products are generally available in the form of roll-ons, sticks, aerosols or sprays.

[005] Antiperspirant substances are, in general, comprised of aluminum and/or zirconium hydrochlorides. These substances make it possible to reduce the flow of sweat by forming a plug in the sweat duct.

[006] However, the use of these substances in high concentrations in order to obtain good effectiveness causes difficulties in terms of formulation.

[007] Furthermore, it was observed that the antiperspirant effectiveness of these substances is limited when they are used alone. This implies that these substances need to be applied several times to the skin in order to obtain a satisfactory effective antiperspirant effect.

[008] Finally, these antiperspirant substances can also leave traces when they are applied, which has the consequence of staining clothes.

[009] In order to overcome all these disadvantages mentioned previously in the present application, it was proposed to search for other effective active substances, which are tolerated by the skin and easy to formulate.

[010] It has already been proposed in US patent application 20070196303 to use calcium-type and/or strontium-type cations in the presence of a buffer comprising an amino acid and a betaine, in order to reinforce the activity of aluminum hydrochloride.

[011] It has also been proposed in application WO 0010512 to use calcium-type cations in the presence of an acidic solution with an amino acid base and/or hydroxy acid, in order to reinforce the activity of aluminum and/or zirconium salts. The presence of aluminum and/or zirconium salts remains mandatory in these antiperspirant formulations.

[012] As an alternative to aluminum and/or zirconium hydrochlorides, a multicomponent antiperspirant agent comprising a first component comprising a cosmetic composition A and a second component comprising a cosmetic composition B has already been proposed in patent WO 2013/013902. other than cosmetic composition A, intended to be mixed prior to application to the skin or to be applied to the skin, simultaneously, separately or delayed over time, said cosmetic composition A comprising a multivalent cation halide, and said composition B comprising a salt of a non-nitrogen-containing anion. The method of application is, however, quite restrictive for the consumer.

[013] As such, there is therefore a real need to apply to the skin an agent intended for the treatment of human perspiration that does not have all the disadvantages described above, that is, that provides a satisfactory antiperspirant effect, in particular, in terms of effectiveness and resistance to sweat, and is well tolerated by the skin. Furthermore, there is a need for such an agent for the treatment of human perspiration, which can be used alone or in combination with an additional antiperspirant agent. Finally, this agent must be able to be formulated in a way that is storage stable.

[014] The Applicant has surprisingly discovered that this objective can be achieved by resorting to a cosmetic method for treating human perspiration and, optionally, body odors resulting from perspiration, which includes the use of at least one Xn+ cation of valence n, at least a Ym- anion of valence m and at least one modulating agent.

[015] The invention therefore relates to a cosmetic method for treating human perspiration and, optionally, body odors resulting from perspiration, which includes the use of at least one Xn+ cation of valence n, at least one Ym anion - of valence m and at least one modulating agent.

[016] When the cation Xn+ of valence n, the anion Ym- of valence m and the modulating agent are formulated in an anhydrous medium, they can be present within the same composition (i.e., a single composition).

[017] Alternatively, they can be formulated in two different compositions, one comprising the cation Xn+ of valence n (composition A), and the other comprising the anion Ym- of valence m (composition B). The modulating agent may, however, be present in composition A and/or composition B. According to an alternative, the modulating agent is not introduced into composition A or composition B, but is generated during mixing between compositions A. and B.

[018] When the cation in oil), the cation is necessarily formulated in a separate composition from the anion.

[019] As such, in this embodiment, preferably: - the cation Xn+ of valence n is present in a composition A; - the anion Ym- of valence m is present in a composition B, the compositions A and B being different, and the composition A and/or B comprising at least one aqueous phase; and - the modulating agent is present in composition A and/or composition B. According to an alternative, the modulating agent is not introduced into composition A or composition B, but is generated during mixing between compositions A and B.

[020] Preferably, this invention relates to a cosmetic method for treating human perspiration and, optionally, body odors resulting from perspiration, which includes: (i) both mixing shortly before use of at least one composition A and of at least one composition B, said compositions A and B being packaged separately, followed by applying the resulting mixture to the surface of the skin; (ii) as applying to the surface of the skin, simultaneously or sequentially, at least one composition A and at least one composition B separately packaged; (iii) or applying to the surface of the skin a composition comprising on the same support at least one composition A and at least one composition B; - said composition A comprising in a cosmetically acceptable medium at least one Xn+ cation of valence n; - said composition B comprising in a cosmetically acceptable medium at least one Ym- anion of valence m; - mixing said composition A with said composition B further comprising at least one modulating agent.

[021] According to a first embodiment, the modulating agent may, however, be present in composition A and/or composition B.

[022] According to a second embodiment, it may also not be present in composition A or composition B, but be generated in situ after mixing said compositions A and B.

[023] This method according to the invention is effective in treating human perspiration. Furthermore, compositions A and B are storage stable.

[024] This invention also relates to a cosmetic composition, in particular for the treatment of human perspiration and, optionally, body odors resulting from perspiration, ready for use, which includes, in a cosmetically acceptable medium, at least one Xn+ cation of valence n, at least one Ym- anion of valence m and at least one modulating agent. This composition is called a “ready-to-use composition” in this application.

[025] The term “ready to use” means that the composition is applied to the surface of the skin within a very short period of time after preparing it, for example, from a few seconds to a few minutes after preparing it. . Typically, the time between mixing the cation(s) to 10 minutes, preferably 0 to 1 minute, and preferably 0 to 30 seconds.

[026] The term “antiperspirant agent” means any substance or any composition that has the effect of reducing the flow of sweat and/or reducing the moist sensation on the skin associated with human sweat and/or masking human sweat.

[027] The term “cosmetically acceptable medium” means a medium compatible with the skin and/or integuments or mucosa thereof, which has a pleasant color, smell and texture and does not generate unacceptable discomfort (such as impermeability), likely to dissuade the consumer from use the composition.

[028] Said cosmetically acceptable means is also a means that does not leave traces during its application, and that, as such, does not stain clothes.

[029] Said cosmetically acceptable medium may be anhydrous or include an aqueous phase. Preferably, it comprises an aqueous phase. Preferably, in particular, the cosmetically acceptable medium of the ready-to-use composition comprises an aqueous phase.

[030] The term “Xn+ cation” means an ionic compound, preferably inorganic, that comprises one or more positive charges; the valence n indicating the number of positive charges.

[031] The term “Ym- anion” means an ionic compound, preferably inorganic, that comprises one or more negative charges; the valence m indicating the number of negative charges.

[032] The term “sequential” means successive administration.

[033] The term “same support” means that compositions A and B according to the invention are present in the same packaging, in particular, in a two-compartment packaging that allows simultaneous applications of compositions A and B.

CATION XN+

[034] The Xn+ cations, according to the invention, are preferably chosen from multivalent inorganic cations whose valence n is by definition at least 2, preferably 2, 3 or 4.

[035] The multivalent inorganic cations Xn+ are Petition 870220069975, of 08/05/2022, p. 18/97 preferably chosen from: - alkaline earth cations such as Magnesium (Mg2+) or Calcium (Ca2+); and - transition metal cations such as Titanium (Ti4+), Manganese (Mn2+, Mn3+, Mn4+), Iron (Fe2+, Fe3+), Copper (Cu2+), Zinc (Zn2+) or Zirconium (Zr4+).

[036] Multivalent inorganic cations Xn+ are preferably chosen from alkaline earth cations.

[037] The preferred alkaline earth cations will be chosen from Magnesium (Mg2+) and Calcium (Ca2+).

[038] The transition metal cations will be chosen from Zinc, Manganese, Iron and Titanium.

[039] The cations, according to the invention, are introduced into the single anhydrous composition, composition A or the ready-to-use composition, in the form of water-soluble salts. In terms of this invention, the term "water-soluble salt" means any salt which, after being completely dissolved with stirring at 0.5% in a water solution at a temperature of 25°C, leads to a solution comprising an amount of insoluble salt less than 0.05% by weight.

[040] Preferably, water-soluble Xn+ cation salts are chosen from halides, sulfates and carboxylates.

[041] In fact, among the Xn+ cation salts that can be used according to the invention, halides can be mentioned. As halides, fluorides (Fluorine), chlorides (Chlorine), bromides (Bromine) and iodides (Iodine) will be used, and more particularly chlorides.

[042] Among the salts of water-soluble Xn+ cations that can be used according to the invention, one can also mention salts of carboxylic acid or carboxylates such as acetates, propionates, depyrrolidone carboxylates (or pidolates); as salts of polyhydroxyl carboxylic acid, as gluconates heptagluconates, keto-glutonates; mono- or polycarboxylic acid hydroxy salts such as citrates, lactates; amino acid salts such as aspartates, glutamates and ascorbic acid salts. More particularly, acetate salts, lactate salts or aspartate salts will be used.

[043] Sulfates can also be mentioned, such as magnesium sulfate, ferric sulfates, zinc sulfates.

[044] As examples of cation salts Calcium Propionate, Calcium 2-Ketogluconate, Calcium Lactate, Calcium Ascorbate, Calcium Citrate, Magnesium Acetate, Magnesium Pidolate, Magnesium Gluconate, Magnesium Glutamate, Magnesium Heptagluconate, Magnesium 2-Ketogluconate, Magnesium Lactate Magnesium, Magnesium Ascorbate, Magnesium Citrate, Magnesium Aspartate or Manganese Gluconate.

[045] One can also mention sulfates, such as magnesium sulfate.

[046] Calcium chloride, Magnesium chloride, Calcium acetate, Magnesium lactate, Calcium citrate and Magnesium citrate will be preferably chosen.

[047] Preferably, composition A comprising at least one Xn+ cation, according to the invention, comprises an aqueous phase and has a pH between 2 and 6, preferably between 3 and 5. If necessary, the pH is adjusted with a cosmetically acceptable organic or mineral acid or base. This acid or base are those conventionally used in cosmetics.

[048] Composition A comprises at least one Xn+ cation of valence n, and does not contain any Ym- anion(s) of valence m as counterion(s).

[049] Preferably, composition A comprises at least one Xn+ cation of valence n in a content between 0.5% and 30%, by weight, of the total weight of composition A, preferably between 1% and 25%, by weight.

[050] Likewise, preferably, the single anhydrous composition comprises at least one Xn+ cation of valence n in a content between 0.5% and 30%, by weight, of the total weight of the composition, preferably between 1% and 25% , by weight.

[051] According to a particular embodiment of the invention, composition A comprises a mixture of Xn+ cations of valence n, and does not contain any anion(s) Ym- of valence m.

[052] According to a preferred embodiment of the invention, composition A comprises an Xn+ cation of valence n, and does not contain any anion(s) Ym- of valence m.

[053] According to another embodiment of the invention, the “ready-to-use composition” comprises an Xn+ cation of valence n, and one or more Ym- anions of valence m, preferably a Ym- anion of valence m.

ANION YM-

[054] The Ym- anions, according to the invention, preferably have an m valence of at least 2, preferably 2, 3 or 4. They are preferably inorganic. They are preferably chosen from carbonate (CO32-), hydrogencarbonate (HCO3-) phosphate (PO43-), polyphosphates such as diphosphate P2O74- (also called pyrophosphate), triphosphate P3O105-, phosphonate (PO33-), hydrogen phosphate (HPO42- ), sulfate (SO42-), sulfonate (SO32-), hydrogensulfate (HSO4-), hydrogensulfonate (HSO3-), silicate (SiO32-). Hydrogen phosphate or hydrogen carbonate will be more particularly used.

[055] The Ym- anions, according to the invention, are introduced into the single anhydrous composition, composition B or the ready-to-use composition, in the form of a water-soluble salt. In terms of this invention, the term “water-soluble salt” of a Ym- anion means any salt which, after being completely dissolved with stirring at 0.5% in a water solution at a temperature of 25°C, takes to a solution comprising an amount of insoluble salt less than 0.05% by weight.

[056] The water-soluble Ym- anion salt can be chosen, for example, from: - alkali metal salts such as potassium, sodium and ammonium salts, such as alkanolamine salts (in particular, monoalkanolamine, dialkanolamine or trialkanolamine ), which comprise one to three C1-C4 hydroxyalkyl radicals, identical or not.

[057] Among the alkanolamine compounds, mention may be made of monoethanolamine, diethanolamine, triethanolamine, monoisopropanolamine, diisopropanolamine, N-dimethylaminoethanolamine, 2-amino-2-methyl-1-propanol, triisopropanolamine, 2-amino-2-methyl-1 ,3-propanediol, 3-amino-1,2-propanediol, 3-dimethylamino-1,2-propanediol, tris-hydroxymethylaminomethane.

[058] Preferably, the Ym- anion will be introduced in the form of an alkali metal salt, in particular, a sodium or potassium salt.

[059] Among the preferred salts of Ym- anion, mention may be made of Na2CO3, K2CO3, NaHCO3, KHCO3, Na3PO3, Na2HPO4, NaH2PO4, Na2H2P2O7, Na4P2O7, K2HPO4, KH2PO4, K2H2P2O7, K4P2O7, Na2SO4, K2SO4. Sodium hydrogen carbonate NaHCO3 or disodium hydrogen phosphate Na2HPO4 will be used preferentially.

[060] The molar ratio between the Xn+ cation or cations and the Ym- anion or anion preferably ranges from 10:1 to 1:10 and more preferably from 4:1 to 1:4.

[061] The total concentration of cation(s) in the ready-to-use composition or in the single anhydrous composition).

[062] Composition B comprises at least one Ym- anion of valence m, and does not contain any Xn+ cation of valence n as a counter-ion.

[063] Preferably, composition B comprises at least one Ym- anion of valence m in a content between 0.5% and 30%, by weight, of the total weight of composition B, preferably between 0.7% and 25%, in weight.

[064] Likewise, preferably, the single anhydrous composition comprises at least one Ym- anion of valence m in a content between 0.5% and 30%, by weight, of the total weight of composition B, preferably between 0.7 % and 25%, by weight.

[065] According to a particular embodiment of the invention, composition B comprises a mixture of Ym- anions of valence m, and does not contain any cation(s) Xn+- of valence n.

[066] According to a preferred embodiment of the invention, composition B comprises Ym- anions of valence m, and does not contain any Xn+ cation(s) of valence n.

[067] According to another embodiment of the invention, the “ready-to-use composition” comprises a Ym- anion of valence m, and one or more Xn+- cations of valence n, preferably an Xn+ cation of valence n.

MODULATORS

[068] As previously indicated in the present application, according to a first embodiment, the modulating agent(s) may, however, be present in composition A and/or in composition B. Preferably, the modulating agent(s) are present in composition A.

[069] According to a second embodiment, it may also not be present in composition A or composition B, but be generated in situ after mixing said compositions A and B.

[070] The modulating agent according to the invention can be chosen from complexing agents for the cation(s) Xn+ and complexing agents for the anion(s) Ym-. Preferably, the modulating agent according to the invention can be chosen from complexing agents of the Xn+ cation(s).

[071] The modulating agent according to the invention is different from the anion(s) Ym- and the cation(s) Xn+.

[072] In particular, it can be chosen from: - monocarboxylic or polycarboxylic acids (preferably dicarboxylic or tricarboxylic), optionally hydroxylated (i.e. hydroxy acids), in free or salified form, such as propionic acid, citric acid, acid tartaric acid, lactic acid, malic acid, succinic acid, glutaric acid, itaconic acid, - amino carboxylic acids in free or salified form such as aspartic acid, glutamic acid, serine, alanine, dehydroalanine and the oligomers thereof, iminosuccinic acid and derivatives thereof, ethylenediaminetetraacetic acid, - monosaccharides, oligosaccharides, polysaccharides and derivatives thereof. Preferably, the monosaccharides are chosen from glucose, galactose, mannose, xylose, lyxose, fucose, arabinose, rhamnose, ribose, deoxyribose, quinovose, fructose, sorbose, thalose, threose and erythrose. Preferably, the oligosaccharides comprise from 2 to 6 monosaccharide units, and are preferably chosen from trehalose, lactose, maltose and cellobiose. Derivatives are preferably chosen from glucuronic and lactobionic acid. Finally, polysaccharides are preferably chosen from chitosan alginates and pectins, Petition 870220069975, of 05/08/2022, p. 24/97 - ascorbic acid, - phytic acid, - polymers or copolymers of carboxylic acids in free or salted form such as products sold under the name SOKOLAN CP42, CP44 by BASF, - polymers or copolymers of amino carboxylic acids in free or salted form , such as polyaspartic acid as, for example, the polymers mentioned in patents WO 9216462, WO 9403527 Srchem Incorp. and, in particular, a 30% solution of sodium polyaspartate in water, such as the product sold under the trade name AQUADEW SPA-30 by Ajinomoto; polyglutamic acid, - polymers or copolymers of maleic or itaconic acid, - polymers or copolymers of carboxymethylinulin.

[073] Among the preferred modulators, when they must be added, amino carboxylic acids in free or salted form, optionally hydroxylated monocarboxylic or polycarboxylic acids in free or salted form, ascorbic acid, polymers or copolymers of amino carboxylic acids in free form will be mentioned. or salified as polyaspartic acid, or polymers or copolymers of carboxylic acids in free or salified form.

[074] Citric acid, ascorbic acid, lactic acid, propionic acid, tartaric acid or polyaspartic acid, in free or salified form, or polymers or copolymers of optionally amino carboxylic acids will be more particularly used.

[075] According to a particular embodiment of the invention, composition A or composition B or the “ready-to-use composition” or the single anhydrous composition, comprises a mixture of modulating agents, preferably two modulating agents.

[076] More preferably, as modulating agents, a mixture of citric acid in free form and citric acid in salified form (or citrate) will be used, in particular, a mixture of citric acid and sodium citrate. More preferably, the weight ratio (citric acid in free form): (citric acid in salified form) is between 1:4 and 1:2.

[077] The modulating agent(s) according to the invention may be present in composition A and/or B (or in the ready-to-use composition or in the single anhydrous composition) in a content between 0.01 and 30%, by weight, of the total weight of composition A and/or B (or the ready-to-use composition or the single anhydrous composition), preferably between 0.03 and 10%, by weight.

[078] Preferably, the ratio, by weight, between the modulating agent(s) and the Xn+ cation salt(s) is between 0.01 and 1.5, preferably between 0 .03 and 1.

[079] Preferably, the composition resulting in the mixture of compositions A and B (or the ready-to-use composition) has a pH between 5 and 8.

APPLICATION METHOD

[080] In order to obtain an antiperspirant effect on the skin, according to a first alternative of the method for treating perspiration of the invention (realization (i)), composition A comprising at least one Xn+ cation and composition B comprising comprises at least one Ym- anion will be packaged separately and are mixed shortly before use (extemporaneous mixing), then the mixture obtained as such is applied to the surface of the skin to be treated.

[081] According to a second alternative of the antiperspirant method of the invention (realization (ii)), composition A comprising at least one Xn+ cation and composition B comprising at least one Ym-anion will be packaged separately and applied simultaneously or sequentially on the surface of the skin to be treated.

[082] According to this alternative, when compositions A and B are applied sequentially, the time interval separating the application of composition A from application B can vary from 1 second to 24 hours, more preferably from 10 seconds to 24 hours and even more preferably from 1 minute to 1 hour.

[083] In order to obtain an antiperspirant effect on the skin, according to a third alternative of the method for treating perspiration of the invention (realization (iii)), a composition comprising on the same support a composition A containing at least one Xn+ cation, composition B containing at least one Ym- anion and at least one modulator.

[084] Compositions A and B may be, each independently, anhydrous or comprise an aqueous phase. They will preferably be in the form of aqueous solutions, alcoholic or hydroalcoholic solutions.

[085] With regard, in particular, to the aforementioned embodiment (iii), compositions A and B can be, for example, packaged in a device comprising at least two compartments containing, respectively, composition A and composition B, such as a double tube, a pump bottle having two compartments, an aerosol device comprising two compartments which may include one or more exit holes (with a nozzle or double nozzle), a device provided with a perforated wall such as a grid comprising two compartments; a device comprising two compartments, each provided with a multi-sphere roll-on applicator; a double stick.

[086] Preferably, compositions A and B will be applied sequentially, and even more preferably, the composition comprising at least one Xn+ cation will be applied first.

[087] Preferably, compositions A and B will be applied sequentially, and even more preferably, composition A comprising at least one Xn+ cation and at least one modulating agent will be applied first. DOSAGE FORMS

[088] Compositions A and/or B (or the ready-to-use composition or the single anhydrous composition), independently of each other, can be presented in any of the dosage forms conventionally used for topical application and, in particular, under in the form of aqueous gels, aqueous or hydroalcoholic solutions. Compositions A and/or B (or the ready-to-use composition) may also be anhydrous. By adding a fat or oil phase, they can be in the form of dispersions such as lotions, emulsions of liquid or semi-liquid consistency such as milk, obtained by dispersing a fat phase in an aqueous phase (O/W) or vice versa (A /O), or suspensions or emulsions of a soft, semi-solid or solid consistency such as cream or gel, or multiple emulsions (W/O/W or O/W/O), microemulsions, dispersions in ionic and/or non-ionic type vesicles or wax/aqueous phase dispersions. These compositions A and/or B (or the ready-to-use composition or the single anhydrous composition) are prepared according to usual methods.

[089] Compositions A and/or B can be particularly packaged in pressurized form in an aerosol device or in a bottle with a pump; packaged in a device equipped with a perforated wall particularly a grid; packaged in a device equipped with a roll-on applicator; packaged in the form of a stick, in the form of loose or compact powder. In this regard, they contain the ingredients generally used in this type of product and well known to those skilled in the art.

[090] According to another particular embodiment of the invention, compositions A and/or B, the ready-to-use composition or the single anhydrous composition, may be solid, in particular, in the form of a stick; loose or compact powder.

[091] The term “solid composition” denotes that the measurement of the maximum force measured by means of texturometric analysis when inserting a probe into the sample of formulas must be at least equal to 0.25 Newton, in particular at least equal to 0, 30 Newton, particularly at least equal to 0.35 Newton, evaluated under accurate measurement conditions as follows.

[092] To carry out texturometric measurements, the formulas are poured when heated into flasks with a diameter of 4 cm and a bottom of 3 cm. Cooling is carried out at room temperature. The hardness of the formulas produced is measured after waiting 24 hours. The bottles containing the samples are characterized through texturometric analysis using a texturometer such as the one sold by Rheo TA-XT2, according to the following protocol: a 5 mm diameter stainless steel ball probe is placed in contact with the sample at a speed of 1 mm/s. The measurement system detects the interface with the sample with a detection threshold equal to 0.005 Newtons. The probe is inserted into the sample 0.3 mm at a rate of 0.1 mm/s. The measuring devices record the progression of the measured compression force over time during the penetration phase. The hardness of the sample corresponds to the average of the maximum values of the force detected during penetration, for at least 3 measurements.

[093] The invention also relates to a method for the cosmetic treatment of human perspiration, and, optionally, body odors associated with human perspiration, which consists of applying to the surface of the skin, in particular the surface of the armpits, an effective amount of the composition A and an effective amount of composition B; or an effective amount of the ready-to-use composition; or an effective amount of the single anhydrous composition.

[094] The application time of composition A and/or B (or the ready-to-use composition or the single anhydrous composition) on the skin surface can vary from 0.5 to 10 seconds, preferably from 1 to 5 seconds.

[095] These compositions A and/or B (or the ready-to-use composition or the single anhydrous composition) can be applied several times to the surface of the skin. They can be applied several times, for one day or for several days.

[096] Another object of this invention is an aerosol device consisting of a first receptacle comprising a pressurized composition A, a second receptacle comprising a pressurized composition B and a means for dispensing the mixture of said composition.

[097] The dispensing means, which form part of the aerosol device, generally consist of a dispensing valve controlled by a dispensing head, which in turn comprises a nozzle through which compositions A and B are sprayed as a mixture . The receptacle containing the pressurized compositions A and B may be opaque or transparent. It can be made of glass, polymeric or metallic material, optionally coated with a layer of protective varnish.

[098] Another object of this invention is an aerosol device comprised of a receptacle comprising an anhydrous composition pressurized in a cosmetically acceptable medium, at least one Xn+ cation of valence n, at least one Ym- anion of valence m and at least one modulating agent ; and a means for dispensing the mixture of said composition.

[099] The dispensing means, which form part of the aerosol device, generally consist of a dispensing valve controlled by a dispensing head, which in turn comprises a nozzle through which the pressurized anhydrous composition is sprayed. The receptacle containing the pressurized anhydrous composition may be opaque or transparent. It can be made of glass, polymeric or metallic material, optionally coated with a layer of protective varnish.

[100] Compositions A and/or B (or the ready-to-use composition or the single anhydrous composition) may also comprise at least one deodorant agent and/or at least one additional antiperspirant agent.

[101] The term “deodorant agent” denotes, in the context of the present invention, any agent, alone, with the effect of masking, absorbing, improving and/or reducing the unpleasant odor resulting from the decomposition of human sweat.

[102] By way of illustration these additional deodorant agents may be, in particular, bacteriostatic agents or bactericidal agents that act on odor germs in the armpits, such as 2,4,4'-trichloro-2'-hydroxydiphenylether (Triclosan®), 2,4-diloro-2'-hydroxydiphenylether, 3',4',5'-trichlorosalicylanilide, 1-(3',4'-dilorophenyl)-3-(4'-chlorophenyl)urea (Triclocarban®) or 3, 7,11-trimethyldodeca-2,5,10-trienol (Farnesol®); quaternary ammonium salts such as cetyltrimethylammonium salts, cetylpyridinium salts; polyols such as those of the glycerin type, 1,3-propanediol (ZEMEA PROPANEDIOL® sold by Dupont Tate and Lyle Bioproducts), 1,2-decanediol (Symclariol® from Symrise); glycerin derivatives such as, for example, Caprylic/Capric glycerides (CAPMUL MCM® from Abitec), Caprylate or glyceryl caprylate (DERMOSOFT GMCY® and DERMOSOFT GMC® respectively from STRAETMANS), Polyglyceryl-2 Caprate (DERMOSOFT DGMC® from STRAETMANS), biguanide derivatives such as polyhexamethylene biguanide salts; chlorhexidine and salts thereof; 4-Phenyl-4,4-dimethyl-2butanol (SYMDEO MPP® from Symrise); cyclodextrins; or alum.

[103] Additional deodorant agents may preferably be present in the compositions according to the invention in mass concentrations ranging from 0.01% to 10%, by weight, relative to the total weight of the composition.

[104] The term “antiperspirant agent” denotes any substance, alone, with the effect of reducing the flow of sweat, reducing the moist sensation on the skin associated with human sweat, masking human sweat.

[105] By way of illustration of these additional antiperspirant agents, mention may be made, in particular, of aluminum and/or zirconium antiperspirant salts or complexes, preferably chosen from aluminum halohydrates; aluminum and zirconium halohydrates, complexes of zirconium hydroxychloridate and aluminum hydroxychloridate with or without an amino acid such as those described in US patent 3792068.

[106] Among the aluminum salts, mention may be made, in particular, of aluminum hydrochloride in activated or non-activated form, aluminum chlorohydrax, polyethylene glycol aluminum chlorohydex complex, propylene glycol aluminum chlorohydex complex, aluminum dihydrochloride, polyethylene glycol complex aluminum dichlorohydrex, propylene glycol aluminum dichlorohydex complex, aluminum sesquihydrochloride, polyethylene glycol aluminum sesquichlorohydex complex, propylene glycol aluminum sesquichlorohydex complex, aluminum sulfate buffered by sodium aluminum lactate.

[107] Among the aluminum and zirconium salts, mention may be made in particular of aluminum zirconium octahydrochloride, aluminum zirconium pentahydrochloride, aluminum zirconium tetrahydrochloride, aluminum zirconium trihydrochloride.

[108] Complexes of zirconium hydroxychloride and aluminum hydroxychloride with an amino acid are generally known under the name ZAG (when the amino acid is glycine). Among these products we can mention complexes of aluminum zirconium octachlorohydex glycine, aluminum zirconium pentachlorohydex glycine, aluminum zirconium tetrachlorohydex glycine and aluminum zirconium trichlorohydex glycine.

[109] Aluminum sesquihydrochloride is in particular sold under the trade name REACH 301® by SUMMITREHEIS.

[110] Among the aluminum and zirconium salts, one can mention the complexes of zirconium hydroxyhydrochloride and aluminum hydroxyhydrochloride with an amino acid such as glycine with the name INCI: ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY, for example, which is sold under the trade name of REACH AZP-908-SUF® by SUMMITREHEIS.

[111] It may be made more particularly from aluminum hydrochloride in activated or non-activated form sold under the trade names LOCRON S FLA®, LOCRON P, LOCRON L.ZA by CLARIANT; under the trade names MICRODRY® ALUMINUM CHHLORHYDRATE, MICRO-DRY 323®, CHLORHYDROL 50, REACH 103, REACH 501 by SUMMITREHEIS; under the trade name WESTCHLOR 200® by WESTWOOD; under the trade name ALOXICOLL PF 40® by GUILINI CHEMIE; CLURON 50%® by INDUSTRIA QUIMICA DEL CENTRO; ALUMINUM CHLOROHYDROXIDE SO A 50%® by FINQUIMICA.

[112] As another antiperspirant agent, expanded perlite particles such as those obtained by the expansion method described in US patent 5,002,698 can be mentioned.

[113] Preferably, compositions A and/or B (or the ready-to-use composition or the single anhydrous composition) comprise less than 5% by weight of aluminum salt, preferably less than 3% by weight, preferably less than 1% by weight.

[114] Preferably, compositions A and/or B (or the ready-to-use composition or the single anhydrous composition) are prepared completely free of aluminum salt.

[115] In the case where compositions A and B are mixed extemporaneously, the dosage forms will preferably be aqueous, alcoholic or hydroalcoholic solutions.

AQUEOUS PHASE

[116] Compositions A and/or B (or the ready-to-use composition) may also comprise at least one aqueous phase. They are formulated particularly in aqueous lotions or in water-in-oil emulsions, an oil-in-water emulsion or in a multiple emulsion (oil-in-water-in-oil or water-in-oil-in-water triple emulsion) (such emulsions are known and described, e.g. by C. FOX in “Cosmetics and Toiletries” - November 1986 - Vol 101 - pages 101 to 112).

[117] The aqueous phase of said compositions A and/or B (or the ready-to-use composition) contains water and other solvents generally water-soluble or water-miscible. Water-soluble or miscible solvents comprise short-chain monoalcohols, for example, C1-C4 such as ethanol, isopropanol; diols or polyols such as ethylene glycol, 1,2-propylene glycol, 1,3-butylene glycol, hexylene glycol, diethylene glycol, dipropylene glycol, 2-ethoxyethanol, diethylene glycol monoethyl ether, triethylene glycol monoethyl ether and sorbitol. Propylene glycol and glycerin, propane 1,3 diol can be used more particularly.

EMULSIFIERS a) Oil-in-water emulsifiers

[118] Compositions A and/or B (or the ready-to-use composition) may also comprise at least one surfactant.

[119] Surfactants can be of any type generally used in cosmetics, such as anionic surfactants, cationic surfactants, amphoteric surfactants or nonionic surfactants.

[120] Preferably, non-ionic surfactants are used such as: C8-C30 (preferably C12-C18) fatty alcohols Petition 870220069975, of 05/08/2022, p. 34/97 polyoxyethylenes, which have, in particular, from 2 to 100 mol of ethylene oxide, such as oxyethylene ether of cetearyl alcohol with 30 oxyethylene groups (CTFA name “Ceteareth-30”), oxyethylene ether of stearyl alcohol with 20 oxyethylene groups (CTFA name “Steareth-20”) such as BRIJ 78 marketed by UNIQEMA or cetearyl alcohol oxyethylene ether with 33 oxyethylene groups (CTFA name “Ceteareth-33”); fatty alcohol and sugar ethers C8-C30, in particular, alkyl (poly)glycosides (C8-C30), alone or in mixtures with alcohols, such as the mixture of cetylstearyl alcohol and cocoglycoside sold under the trade name MONTANOV 82® by Seppic , the mixture of arachidyl alcohol and behenyl alcohol with arachidylglucoside sold under the trade name MONTANOV 802® by Seppic, the mixture of myristyl alcohol and myristylglucoside sold under the trade name MONTANOV 14® by Seppic, the mixture of cetylstearyl alcohol and cetylstearylglucoside sold under the trade name MONTANOV 68® by Seppic, the mixture of C14-C22 alcohol with C12-C20 alkylglucoside sold under the trade name MONTANOV L® by Seppic, the mixture of cocoalcohol and cocoglycoside sold under the trade name MONTANOV S® by Seppic or the mixture of isostearyl alcohol and isostearylglucoside sold under the trade name MONTANOV WO 18® by Seppic; polyethylene glycol ethers, which have, in particular, from 20 to 120 motifs of ethylene oxide and C8-C30 fatty acid esters, and of glucose or methylglucose, C8-C30 fatty acid esters and sorbitan, fatty acid esters C8-C30 and polyoxyethylenated sorbitan, which have, in particular, from 2 to 30 mol of ethylene oxide, polyoxyethylenated fatty acid esters C8-C30 and sorbitan, which have, in particular, from 2 to 100 mol of ethylene oxide, Petition 870220069975, of 05/08/2022, p. 35/97 - monoesters or diesters of C8-C30 fatty acid and glycerol, - polyglycerolated C8-C30 fatty acid esters, which have, in particular, from 2 to 16 mol of glycerol, - esters of C8-C30 fatty acid and polyethylene glycol , which have, in particular, from 2 to 30 mol of ethylene oxide, - esters of C8-C30 fatty acid and glucose or alkyl (C1-C2) glucose or sucrose, and - mixtures thereof.

[121] The surfactant(s) may be present in an amount ranging from 0.1 to 10% by weight in relation to the total weight of composition A or B (or the ready-made composition for use), preferably ranging from 0.2 to 5% by weight, and preferably ranging from 1% to 4% by weight. b) Water-in-oil emulsifiers

[122] Among the emulsifiers that can be used in water-in-oil emulsions or triple water-in-oil-in-water-in-oil emulsions or triple emulsions, alkyl dimethicone can be mentioned as an example. wherein: R1 designates a linear or branched alkyl group C12 to C20 and preferably C12 to C18; R2 designates the group: -CnH2n-(-OC2H4-)x-(-OC3H6-)yO-R3, R3 represents a hydrogen atom or a linear or branched alkyl radical having 1 to 12 carbon atoms; a is an integer ranging from 1 to about 500; b designates an integer ranging from 1 to about 500; n is an integer ranging from 2 to 12 and preferably from 2 to 5; x designates an integer ranging from 1 to about 50 and preferably from 1 to 30; Y designates an integer ranging from 0 to about 49 and preferably 0 to 29, with the proviso that when y is non-zero, the x/y ratio is greater than 1 and preferably ranges from 2 to 11.

[123] Among the preferred alkyldimethicone copolyol emulsifiers having formula (I), Cetyl PEG/PPG-10/1 DIMETHICONE and more particularly the mixture Cetyl PEG/PPG-10/1 DIMETHICONE and Dimethicone (INCI name) will be particularly mentioned. as the product sold under the trade name ABIL EM90 by GOLDSCHMIDT, LAURIL PEG/PPG-18/18 methicone and more particularly the mixture LAURIL PEG/PPG-18/18 methicone and DODECENE and POLOXAMER 407 as the product sold under the trade name of DOW CORNING 5200 FORMULATION AID by DOW CORNING or the mixture (Polyglyceryl-4-stearate and Cetyl PEG/PPG-10a (and) Dimethicone (and) Hexyl Laurate) as the product sold under the trade name ABIL WE09 by GOLDSCHMIDT.

[124] Among water-in-oil emulsifiers, one can also mention copolyol dimethicones which have the following formula (II) where R4 designates the group: -CmH2m-(-OC2H4-)s-(-OC3H6-)tO-R5, Petition 870220069975, of 05/08/2022, p. 37/97 R5 designates a hydrogen atom or a linear or branched alkyl radical having from 1 to 12 carbon atoms; c is an integer ranging from 1 to about 500, d designates an integer ranging from 1 to about 500, n is an integer ranging from 2 to 12 and preferably 2 to 5, s designates a number integer ranging from 1 to about 50 and preferably from 1 to 30; t designates an integer ranging from 0 to 50 and preferably from 0 to 30; as long as the sum s+t is greater than or equal to 1.

[125] Among these preferred dimethicone copolyol emulsifiers having formula (II) use will be made, in particular, of PEG-18/PPG-18 Dimethicone and more particularly the mixture CYCLOPENTASILOXANE (and) PEG-18/PPG-18 DIMETHICONE ( INCI name) as the product sold by Dow Corning under the trade name Silicone DC 5225 C or KF-6040 by Shin Etsu.

[126] According to a particularly preferred embodiment, a mixture of at least one emulsifier having formula (I) and at least one emulsifier having formula (II) will be used.

[127] Use will be made more particularly of a mixture of PEG-18/PPG-18 Dimethicone and Cetyl PEG/PPG-10/1 DIMETHICONE, LAURYL PEG/PPG-18/18 methicone and even more particularly a mixture of (CYCLOPENTASILOXANE ( e) PEG-18/PPG-18 Dimethicone) and Cetyl PEG/PPG-10/1 DIMETHICONE and Dimethicone or (Polyglyceryl-4-stearate and Cetyl PEG/PPG-10 (e) Dimethicone (a) Hexyl Laurate) or the mixture LAURYL PEG/PPG-18/18 methicone and DODECENE and POLOXAMER 407.

[128] Among water-in-oil emulsifiers, one can also mention non-ionic emulsifiers derived from fatty acids and polyols, alkylpolyglycosides (APG), sugar esters and mixtures thereof.

[129] As nonionic emulsifiers derived from fatty acids and polyol, it is possible to use in particular, esters of fatty acids and polyol, the fatty acid in particular having a C8-C24 alkyl chain, and the polyols being, for example, glycerol and sorbitan.

[130] As esters of fatty acids and polyols, one may mention, in particular, esters of isostearic acid and polyols, esters of stearic acid and polyols, and mixtures thereof, in particular, esters of isostearic acid and glycerol and/or of sorbitan.

[131] Alkyl polyol esters particularly include polyethylene glycol esters such as PEG-30 Dipolyhydroxystearate, such as the product marketed under the name Arlacel P135 by ICI.

[132] Glycerol and/or sorbitan esters include, for example, polyglycerol isostearate, such as the product marketed under the name Isolan GI 34 by Goldschmidt; sorbitan isostearate, such as the product marketed under the name Arlacel 987 by ICI; sorbitan isostearate and glycerol, such as the product marketed under the name Arlacel 986 by ICI, the mixture of sorbitan isostearate and polyglycerol isostearate (3 mol), marketed under the name Arlacel 1690 by Unigema and mixtures thereof.

[133] The emulsifier can also be chosen from alkylpolyglycosides that have an HLB less than 7, for example, those represented by the following general formula (1): R-O-(G)x (1)

[134] where R represents a branched and/or unsaturated alkyl radical, comprising 14 to 24 carbon atoms, G represents a reduced sugar, comprising 5 to 6 carbon atoms, and x represents a value ranging from 1 to 10 and preferably from 1 to 4, and G designates, in particular, glucose, fructose or galactose.

[135] The unsaturated alkyl radical may comprise one or more ethylene unsaturations and, in particular, one or two ethylene unsaturations.

[136] As alkylpolyglycosides of this type, one can mention alkylpolyglycosides (G = glucose in formula (1)) and, in particular, compounds having formula (I) in which R more particularly represents an oleyl radical (unsaturated radical C18) or isostearyl (saturated radical C18), G designates glucose, x is a value ranging from 1 to 2, in particular, isostearyl-glucoside, oleyl-glucoside, and mixtures thereof. This alkylpolyglucoside can be used in a mixture with a coemulsifier, more especially with a fatty alcohol and, in particular, a fatty alcohol having the same fatty chain as that of the alkylpolyglucoside, i.e. comprising from 14 to 24 carbon atoms and which has a branched and/or unsaturated chain and, for example, isostearyl alcohol when the alkylpolyglucoside is isostearyl glucoside, and oleyl alcohol when the alkylpolyglucoside is oleyl glucoside, optionally in the form of a self-emulsifying composition as described, e.g. , in WO A-92/06778. For example, it is possible to use the mixture of isostearyl glucoside and isostearyl alcohol, sold under the trade name Montanov WO 18 by SEPPIC, as well as the mixture of octyldodecanol and octyldodecylxyloside sold under the name FLUDANOV 20X by SEPPIC.

[137] One may also mention polyolefins with a succinic termination, such as polyisobutylenes with an esterified succinic termination and salts thereof, in particular, diethanolamine salts, such as the products marketed under the names Lubrizol 2724, Lubrizol 2722 and Lubrizol 5603 by Lubrizol or the commercial product CHEMCINNATE 2000.

[138] The total amount of emulsifier(s) in composition A or B (or in the ready-to-use composition) should preferably have active material contents ranging from 1 to 8% by weight, and more particularly from 2 to 6% by weight in relation to the total weight of the composition.

[139] According to a particular embodiment of the invention, compositions A and/or B (or ready-to-use composition) in the form of an emulsion can be prepared according to the reverse phase manufacturing technique. This technique is, in principle, well known and, in particular, described in the article “Phase Inversion Emusification”, by Th Forster etal, published in Cosmetics & Toiletries, vol. 106, December 1991, pages 49 to 52. Its principle is as follows: (i) In the presence of a suitable emulsification system, with stirring, an oily phase, on the one hand, and an aqueous phase, on the other hand, being mixed, said mixing being carried out at a temperature higher than the phase inversion temperature (PIT) of the medium, in order to obtain a water-in-oil type emulsion; (ii) The temperature of the emulsion obtained as such is brought to a temperature lower than said phase inversion temperature, whereby an ultrafine oil-in-water type emulsion is obtained; (iii) mineral nanopigments are then introduced during the implementation of step (i) and/or at the end of step (ii).

[140] Suitable systems are non-ionic type emulsifiers and are chosen from polyoxypropylenated and/or polyoxyethylenated fatty alcohols (i.e., compounds obtained by a reaction between an aliphatic fatty alcohol, such as behenyl alcohol or cetyl alcohol, with ethylene or propylene oxide, or a mixture of ethylene oxide/propylene oxide) and the esters of fatty acids and polyols, optionally polyoxyethylenated and/or polyoxypropylenated (i.e. compounds obtained by a reaction of a fatty acid, such as acid stearic or oleic acid, with a polyol such as, for example, an alkylene glycol or glycerol, or a polyglycerol, optionally in the presence of ethylene oxide or propylene oxide, or a mixture of ethylene oxide/oxide Petition 870220069975, of 05/08 /2022, page 41/97 of propylene), or mixtures thereof.

[141] Furthermore, and preferably, the retained emulsification system will have a total HLB (HLB = Hydrophilic-Lipophilic Balance) in Griffin's terms; see J. Soc. Cosm. Chem. 1954 (vol 5), pages 249 to 256; balance between the hydrophilic nature and the lipophilic nature of the surfactant), ranging from 9.5 to about 11.5, advantageously close to 10, so as to make it possible to obtain a phase inversion at a temperature lower than 90°C (TIP < 90°C).

[142] The content of the emulsifying agent(s) is between 0.5 and 40% by weight, and preferably between 2 and 10% by weight, relative to the total weight of the emulsion.

OIL PHASE

[143] Compositions A and/or B (or the ready-to-use composition or the single anhydrous composition) may contain at least one water-immiscible organic liquid phase, known as a fatty acid phase. This generally includes one or a plurality of hydrophobic compounds that produce said water-immiscible phase. Said phase is liquid (in the absence of a structuring agent) at room temperature (20 to 25°C). Preferably, the water-immiscible organic liquid phase according to the invention is generally comprised of at least one volatile oil and/or a non-volatile oil and optionally at least one structuring agent.

[144] “Oil” means a liquid fatty body at room temperature (25°C) and atmospheric pressure (760 mm Hg: 105 Pa). Oil can be volatile or non-volatile.

[145] The term “volatile oil”, according to the invention, denotes any oil capable of evaporating in contact with the skin or keratin fibers, in less than one hour at room temperature and atmospheric pressure. The volatile oils according to the invention are cosmetic volatile oils, which are liquids at room temperature, with a non-zero vapor pressure, at room temperature and at atmospheric pressure, particularly ranging from 0.13 Pa to 40,000 Pa (10- 3 to 300 mm Hg), particularly ranging from 1.3 Pa to 13,000 Pa (0.01 to 100 mm Hg), and more specifically ranging from 1.3 Pa to 1300 Pa (0.01 to 10 mm Hg).

[146] The term “nonvolatile oil” denotes an oil remaining on the skin or keratin fibers at room temperature and atmospheric pressure for at least several hours and particularly with a vapor pressure of less than 10-3 mm Hg (0.13 Pa ).

[147] The oil can be chosen from any physiologically acceptable and cosmetically acceptable oil, in particular mineral, animal, vegetable, synthetic oil; in particular, volatile or non-volatile hydrocarbon and/or silicone and/or fluorinated oils and mixtures thereof.

[148] More specifically, the term “hydrocarbon oil” denotes an oil that essentially comprises carbon and hydrogen atoms and optionally one or a plurality of functions chosen from hydroxyl, ester, ether, carboxylic. Generally, the oil has a viscosity of 0.5 to 100,000 mPa.s, preferably 50 to 50,000 mPa.s and more preferably 100 to 300,000 mPa.s.

[149] By way of examples of volatile oils suitable for use in the invention, it may be mentioned: - volatile hydrocarbon oils chosen from hydrocarbon oils with 8 to 16 carbon atoms, and particularly petroleum-based isoalkanes C8- C16 (also cited as isoparaffins) such as isododecane (also cited as 2,2,4,4,6-pentamethylheptane), isodecane, isohexadecane and, for example, oils sold under the trade names Isopars or Permetyls, C8-C16 branched esters, isohexyl neopentanoate and mixtures thereof. Additional volatile hydrocarbon oils, such as petroleum distillates, particularly those sold under Shell's Shell Solt name, may also be used; volatile linear alkanes such as those described in Cognis patent application DE10 2008 012 457; - volatile silicones such as, for example, linear or cyclic volatile silicone oils, particularly those that have a viscosity of < 8 centistokes (810-6 m2/s), and that have in particular 2 to 7 silicone atoms, these silicones optionally comprising alkyl or alkoxy groups having 1 to 10 carbon atoms. Mention may be made as a volatile silicone oil suitable for use in the invention, in particular, of octamethyl cyclotetrasiloxane, decamethyl cyclopentasiloxane, dodecamethyl cyclohexasiloxane, heptamethyl hexyltrisiloxane, heptamethyloctyl trisiloxane, hexamethyl disiloxane, octamethyl trisiloxane, decamethyl tetrasiloxane, dodecamethyl pentasiloxane; - and mixtures thereof.

[150] Volatile alkyl trisiloxane oils with general formula (I) can also be mentioned: wherein R represents an alkyl group comprising 2 to 4 carbon atoms and wherein one or more hydrogen atoms may be replaced by a fluorine or chlorine atom.

[151] Among the oils with general formula (I), one can mention: 3-butyl 1,1,1,3,5,5,5-heptamethyl trisiloxane, 3-propyl 1,1,1,3,5 ,5,5-heptamethyl trisiloxane, and 3-ethyl 1,1,1,3,5,5,5-heptamethyl trisiloxane, which correspond to the oils having formula (I) for which R is respectively a butyl group, a propyl group or an ethyl group.

[152] Through examples of non-volatile oils suitable for Petition 870220069975, dated 05/08/2022, p. 44/97 use in the invention, it may be mentioned: - vegetable-based hydrocarbon oils such as liquid fatty acid triglycerides having 4 to 24 carbon atoms such as heptanoic or octanoic triglycerides or wheat germ, olive oil, sweet almond, palm , rapeseed, cotton, coconut, alfalfa, poppy seed, pumpkin seed, pumpkin, currant seed, evening primrose, millet, barley, quinoa, rye, safflower, walnut, passion fruit, rosehip, sunflower, corn, soybeans, pumpkin, grape seed, sesame, hazelnut, apricot, macadamia, castor, avocado oil, caprylic/capric acid triglycerides such as those sold by Stearineries Dubois or those sold under the trade names Miglyol 810, 812 and 818 by SASOL, jojoba, shea butter; - linear or branched hydrocarbons of mineral or synthetic origin, such as liquid paraffins and derivatives thereof, petroleum jelly, polydecenes, polybutenes, hydrogenated polyisobutene such as Parleam, squalane; - synthetic ethers that have 10 to 40 carbon atoms; - synthetic esters, in particular, fatty acids such as oils having the formula R1COOR2 wherein R1 represents the residue of a linear or branched higher fatty acid comprising 1 to 40 carbon atoms and R2 represents a hydrocarbon chain, particularly branched containing 1 to 40 carbon atoms with Ri + R2 > 10 such as Purceline oil (cetostearyl octanoate)), isononyl isononanoate, isopropyl myristate, isopropyl palmitate, C12 to C15 alcohol benzoate, hexyl laurate, diisopropyl adipate, 2-ethylhexyl palmitate, octyl-2-dodecyl stearate, octyl-2-dodecyl erucate, isostearyl isostearate, tridecyl trimellitate; octanoates, decanoates or ricinoleates of alcohols or polyalcohols such as propylene glycol dioctanoate; hydroxylated esters such as isostearyl lactate, octyl hydroxy stearate, octyldodecyl hydroxystearate, diisostearyl malate, triisocetyl citrate; heptanoates, octanoates, decanoates of fatty alcohols; polyol esters such as propylene glycol dioctanoate, neopentyl glycol diheptanoate and diethylene glycol diisononanoate; and pentaerythritol esters such as pentaerythrityl tetraisostearate; - fatty alcohols that are liquid at room temperature, with a branched and/or unsaturated carbon chain that has 12 to 26 carbon atoms, such as octyldodecanol, isostearyl alcohol, 2-butyl octanol, 2-hexyl decanol, 2-undecylpentadecanol, linoleyl alcohol oleylic; - higher fatty acids such as oleic acid, linoleic acid, linolenic acid; - fluorinated oils, optionally partially hydrocarbon-based and/or silicone-based, such as fluorosilicone oils, fluorinated polyethers or fluorinated silicones, as described in document EP-A-847 752; - silicone oils such as polydimethylsiloxanes (PDMS) which are non-volatile and linear or cyclic; polydimethylsiloxanes comprising alkyl, alkoxy or phenyl groups pendant to or at the end of the silicone chain, said groups having from 2 to 24 carbon atoms; phenylated silicones, such as phenyl trimethicones, phenyl dimethicones, phenyltrimethylsiloxydiphenylsiloxanes, diphenyl dimethicones, diphenylmethyldphenyltrisiloxanes or (2-phenylethyl)trimethylsiloxysilicates; and - mixtures thereof.

SOLID FATS

[153] Compositions A and/or B (or the ready-to-use composition or the single anhydrous composition) may comprise at least one solid fat, preferably chosen from waxes and pasty fatty substances, and mixtures thereof, and more particularly waxes.

PASTY GREASY SUBSTANCES

[154] The term “pasty fatty substance” (or pasty compound) refers to a lipophilic fatty compound that has a reversible solid/liquid state change, that has an anisotropic crystalline organization in the solid state, and that comprises a liquid fraction and a solid fraction, at a temperature of 23°C.

[155] In other words, the melting point of the pasty compound may be less than 23°C. The liquid fraction of the pasty compound measured at 23°C can represent 9% to 97% by weight of the compound. This liquid fraction at 23°C preferably represents between 15% and 85% by weight, more preferably between 40% and 85% by weight. According to the invention, the melting point is equivalent to the temperature of the maximum endothermic peak observed in thermal analysis (DSC), as described in ISO 11357-3; 1999. The melting point of a paste or wax can be measured using a differential scanning calorimeter (DSC), for example, the calorimeter sold under the name “MDSC 2920” by 45 TA Instruments.

[156] The measurement protocol is as follows: a 5 mg sample of pasty compound or wax (according to the case) placed in a crucible is subjected to a first temperature rise from -20°C to 100°C, at a heating rate of 10°C/minute and then cooled from 100°C to - 20°C at a cooling rate of 10°C/minute and finally subjected to a second temperature rise of -20°C to 100°C at a heating rate of 5°C/minute. During the second rise in temperature, the variation in the difference in energy absorbed by the empty crucible and the crucible containing the sample of pasty compound or wax as a function of temperature is measured.

[157] The melting point of the compound is the value of the equivalent and temperature for the upper point of the peak of the curve representing the variation in the difference in absorbed energy as a function of temperature.

[158] The liquid fraction, by weight, of the pasty compound at 23ºC is equal to the ratio of the fusion enthalpy consumed at 23ºC to the fusion enthalpy of the pasty compound.

[159] The enthalpy of melting of the pasty compound is the enthalpy consumed by the compound to change from the solid to the liquid state. A pasty compound is said to be in a solid state when its entire solid mass is in crystalline form. A pasty compound is said to be in a liquid state when its entire mass is in liquid form.

[160] The enthalpy of fusion of the pasty compound is equal to the area under the curve of the thermogram obtained using a differential scanning calorimeter (DSC), such as the calorimeter sold under the name MDSC 2920 by TA instrument, with an increase in temperature 5°C or 10°C per minute, in accordance with ISO 11357-3:1999. The enthalpy of fusion of the pasty compound is the amount of energy required to change the compound from the solid to the liquid state. It is expressed in J/g. The enthalpy of fusion consumed at 23°C is the amount of energy required by the sample to change from the solid state to the state presented at 23°C that consists of a liquid fraction and a solid fraction.

[161] The liquid fraction of the pasty compound measured at 32°C, preferably represents 30% to 100%, by weight, of the compound, preferably 50% to 100%, by weight, more preferably 60% to 100%, in weight of the compound. If the liquid fraction of the pasty compound measured at 32°C is equal to 100%, the temperature at the end of the melting range of the pasty compound is less than or equal to 32°C.

[162] The liquid fraction of the pasty compound at 32°C is equal to the ratio of the fusion enthalpy consumed at 32°C to the melting enthalpy of the pasty compound. The fusion enthalpy consumed at 32°C is calculated according to the fusion enthalpy consumed at 23°C.

[163] The pasty compound is preferably chosen from synthetic compounds and plant-based compounds. A pasty compound can be obtained by synthesis from plant-based starting materials. The pasty compound is advantageously chosen from: - lanolin and derivatives thereof; - polyol ethers chosen from pentaerythritol and polyalkylene glycol ethers, fatty alcohols and sugar ethers, and mixtures thereof, pentaerythritol ether and polyethylene glycol comprising 5 oxyethylene units (OE 5) (CTFA name: PEG-5 Pentaerythrityl Ether ), pentaerythritol ether and polypropylene glycol comprising 5 oxypropylene units (5 OP) (CTFA name: PPG-5 Pentaerythrityl Ether), and mixtures thereof, and more specifically the mixture of PEG-5 Pentaerythrityl Ether, Pentaerythrityl Ether of PPG-5 and soybean oil, sold under the name “Lanolide” by Vevy, in which the ratio of constituents, by weight, is 46:46:8. PEG-5 Pentaerythrityl Ether 46%, PPG-5 Pentaerythrityl Ether 46% and soybean oil 8%; - optionally polymeric silicone compounds; - optionally polymeric fluorinated compounds; - vinyl polymers, in particular, olefin homopolymers and copolymers, hydrogenated homopolymers and copolymers, linear or branched oligomers, alkyl (meth)acrylate homopolymers or copolymers preferably having a C8-C30 alkyl group, homopolymer oligomers and vinyl ester copolymers , which have C8-C30 alkyl groups, homopolymer oligomers and vinyl ether copolymers, which have C8-C30 alkyl groups; - fat-soluble polyethers derived from polyetherification between one or a plurality of C2-C100 diols, preferably C2-C50; - esters; - and/or mixtures thereof.

[164] The pasty compound is preferably a polymer, in particular, a hydrocarbon.

[165] Preference is given to fat-soluble polyethers, in Petition 870220069975, dated 05/08/2022, p. 49/97 in particular, to copolymers of ethylene oxide and/or propylene oxide with C6-C30 long-chain alkylene oxides, more preferably, so that the ratio, by weight, of ethylene oxide and/or propylene oxide with alkylene oxides in the copolymer is 5:95 to 70:30.

[166] In this family, in particular, one can mention copolymers such that long-chain alkylene oxides arranged in blocks having an average molecular weight of 1,000 to 10,000, for example, a polyoxyethylene glycol/polydodecyl glycol block copolymer such as dodecanediol (22 mol) and polyethylene glycol ethers (45 OE), sold under the brand name ELFACOS ST9 by Akzo Nobel.

[167] Among the esters, particular preference is given to: - glycerol oligomer esters, especially diglycerol esters, particularly adipic acid and glycerol condensates, for which part of the hydroxyl groups of the glycerols have reacted with a mixture of fatty acids as acid stearic acid, capric acid, stearic acid and isostearic acid and 12-hydroxystearic acid, particularly as sold under the brand name Softisan 649 by Sasol; - arachidyl propionate sold under the brand name Waxenol 801 by Alzo; - phytosterol esters; - triglycerides of fatty acids and derivatives thereof; - pentaerythritol esters; - non-crosslinked polyesters derived from polycondensation between a dicarboxylic acid or a linear or branched C4-C50 carboxylic acid and a diol or a C2-C50 polyol; - aliphatic esters of esters derived from 4 to 30 and preferably 8 to 30 carbon atoms. It is preferably chosen from hexanoic acid, heptanoic acid, octanoic acid, ethyl-2 hexanoic acid, nonanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, tridecanoic acid, tetradecanoic acid, pentadecanoic acid, hexadecanoic acid, heptadecanoic acid, hexyldecanoic acid , octadecanoic acid, isostearic acid, nonadecanoic acid, eicosanoic acid, isoarachidic acid, octyldodecanoic acid, heneicosanoic acid, docosanoic acid, and mixtures thereof. Aliphatic carboxylic acid is preferably branched. The aliphatic hydroxycarboxylic acid ester is advantageously derived from a hydroxylated aliphatic carboxylic acid comprising 2 to 40 carbon atoms, preferably 10 to 34 carbon atoms and more preferably 12 to 28 carbon atoms, and 1 to 20 hydroxyl groups. preferably 1 to 10 hydroxyl groups and more preferably 1 to 6 hydroxyl groups.

[168] The aliphatic hydroxy carboxylic acid ester is, in particular, chosen from: a) partially or fully saturated linear monohydroxylated aliphatic monocarboxylic acid esters; b) esters of partially or fully unsaturated linear monohydroxylated aliphatic monocarboxylic acids; c) esters of partially or fully saturated non-hydroxylated aliphatic carboxylic acids; d) esters of partially or fully saturated non-polyhydroxylated aliphatic carboxylic acids; e) esters of partial or total C2 to C16 aliphatic polyols, which reacted with a monohydroxylated or polyhydroxylated aliphatic carboxylic monoacid or polyacid, and mixtures thereof, f) esters of diol dimers and diacid dimers, Petition 870220069975, of 05/08 /2022, p. 51/97 optionally esterified in alcohol or free from acid function(s), or alcohol radicals, particularly dilinoleate dimer esters, such esters may particularly be chosen from esters having the following INCI classification: bis-phenyl/isostearyl/phytosteryl dimerdilinoleyl dimerdilinoleate (Plandool G), phytosteryl/isosteryl/cetyl/stearyl/beenyl dimerdilinoleate (Plandool H or Plandool S), and mixtures thereof; g) hydrogenated rosinate esters, such as dilinoleyl dimer hydrogenated rosinates (Lusplan DD-DHR or DD-DHR from Nippon Fine Chemical); and h) mixtures thereof.

WAXES

[169] According to a preferred embodiment, composition A and/or B (or the ready-to-use composition or the single anhydrous composition) comprises at least one wax.

[170] Generally, a wax in the structure of this invention is considered to be a lipophilic compound, which is solid at room temperature (25°C), which has a reversible solid/liquid state change and a melting point greater than or equal to at 30°C to up to 200°C and particularly up to 120°C. In particular, waxes suitable for the invention may have a melting point greater than or equal to 45°C, and particularly greater than or equal to 55°C. Waxes suitable for use in compositions A and/or B (or the ready-to-use composition) are chosen from animal, vegetable, mineral or synthetic waxes, which are solid at room temperature, and mixtures thereof.

[171] Mention may be made, for example, of the following hydrocarbon waxes comprising a fatty alkyl chain having in general from 10 to 60 carbon atoms, preferably from 20 to 40 carbon atoms, said chain capable of being saturated or unsaturated, substituted or not, linear, branched or cyclic, preferably saturated and linear: - fatty alcohols; - esters of fatty alcohols; - fatty acids; - fatty acid amides; - esters of fatty acids, including triglycerides; - fatty acid ethers; - ethoxylated fatty alcohols; - ethoxylated fatty alcohols, and the corresponding salts thereof.

[172] Among fatty alcohols, mention may be made of stearyl, cetearyl alcohol or mixtures thereof.

[173] Among the fatty alcohol esters, mention may be made of triisostearyl citrate, ethylene glycol-di-12-hydroxystearate, triestearylcitrate, stearyl octanoate, stearyl heptanoate, trilauryl citrate, and mixtures thereof. Among the fatty acid esters, one can mention ester waxes, monoglycerides, diglycerides or triglycerides.

[174] As an ester wax, stearyl stearate, stearyl behenate, stearyl octyldodecanol, cetearyl behenate, behenyl behenate, ethylene glycol, distearate, ethylene glycol dimaplimitate can be mentioned. It is possible to use, in particular, a C20C40 alkyl (hydroxystearyloxy stearate) (the alkyl group comprising 20 to 40 carbon atoms), alone or in a mixture, can be used as the wax.

[175] This wax is particularly sold under the names “Kester Wax K 82 P®”, “Hydroxypolyester K 82 P®” and “Kester Wax K 80 P®” by Koster Keunen.

[176] Among triglyceride waxes, mention may be made more particularly of tribeenin, C18-C36 triglycerides, and mixtures thereof.

[177] By way of illustration of waxes suitable for the invention, in particular, mention may be made of hydrocarbon waxes, such as beeswax, lanolin wax, and Chinese insect waxes, rice bran wax, carnauba wax, candellilla wax, ouricuri wax, alfa wax, berry wax, shellac wax, Japan wax and sumac wax, lignite wax, orange and lemon waxes, waxes, paraffins and microcrystalline ozokerites; polyethylene waxes, waxes obtained by Fisher-Tropsch synthesis and wax copolymers and their esters.

[178] One can also mention waxes obtained through catalytic hydrogenation of animal or vegetable oils that have linear or branched C8-C32 fat chains. Of these, in particular, mention may be made of isomerized jojoba oil, such as partially isomerized hydrogenated jojoba oil manufactured or sold by Desert Whale under the trade name Iso-Jojoba-50®, hydrogenated sunflower oil, hydrogenated castor oil, hydrogenated coconut oil, hydrogenated lanolin oil and di-(trimethylol-1,1,1 propane) tetrastearate sold under the name Hest 2T-4S® by Heterene.

[179] Waxes made from silicone (alkyl dimethicone C30-45) and fluorinated waxes can also be mentioned. It is also possible to use waxes obtained by hydrogenation of castor oil esterified with cetyl alcohol sold under the names Phytowax ricin 16L64® and 22L73® by Sophim. Such waxes are, in particular, described in application FR 2 792 190.

[180] As microwaxes that can be used in compositions A and/or B, one can mention, in particular, carnauba microwaxes such as those marketed under the name MicroCare 350® by Micro Powders, synthetic wax microwaxes such as those marketed under the name MicroEase 114S® by Micro Powders, microwaxes formed from a mixture of carnauba wax and polyethylene wax such as those marketed under the name Micro Care 300® and 310® by Micro Powders, microwaxes formed from a mixture Petition 870220069975, of 05/08/2022, p. 54/97 carnauba wax synthetic wax such as those sold under the name Micro Care 325® by Micro Powders, polyethylene microwaxes such as those sold under the name Micropoly 200®, 220®, 220L® and 250S® by Micro Powders and microwaxes polytetrafluoroethylene, such as those sold under the name Microslip 519® and 519 L® by Micro Powders.

[181] Composition A and/or B (or the ready-to-use composition or the single anhydrous composition) may comprise a solid fat content preferably ranging from 1% to 30% by weight, and, in particular, from 2 % to 20%, by weight, in relation to the total weight of the composition.

ADDITIONS

[182] Compositions A and/or B (or the ready-to-use composition or the single anhydrous composition) may also further comprise additional cosmetic agents.

[183] Cosmetic compositions A and/or B (or the ready-to-use composition or the single anhydrous composition), in addition, may comprise cosmetic additives chosen from opacifiers, stabilizers, preservatives, perfumes, sunscreens, cosmetic active agents, fillers , suspending agents, sequestrants, coloring materials or any other ingredient routinely used in cosmetics for this type of application.

[184] Obviously, one skilled in the art will be careful to choose the optional compound(s) such that the advantageous properties intrinsically associated with composition A or B, or with the ready-to-use composition or with the unique anhydrous composition, are not altered, or are not substantially altered, by the anticipated additive(s).

ORGANIC POWDER

[185] According to a particular embodiment of the invention, compositions A and/or B (or the ready-to-use composition or the anhydrous composition) will additionally contain an organic powder.

[186] In this application, the term “organic powder” denotes any solid insoluble in the solid medium at room temperature (25°C).

[187] As organic powders that can be used, one can mention, for example, polyamide particles, particularly those sold under the trade name ORGASOL by Atochem; nylon 6.6 fibers, in particular the polyamide fibers marketed by Etablissements P Bonte under the name Polyamide 0.9 Dtex 0.3 mm (INCI name: Nylon 6.6 or Polyamide- 6.6) which have a medium diameter of 6 μm, a weight of about 0.9 dtex and a length that varies from 0.3 mm to 1.5 mm; powdered polyethylenes; microspheres based on acrylic copolymers, such as ethylene glycol dimethacrylate/lauryl methacrylate copolymers sold by Dow Corning under the trade name POLYTRAP; polymethyl methacrylate microspheres, marketed under the trade name MICROSPHERE M-100 by Matsumoto or under the trade name COVABEAD LH85 by Wackherr; polymethyl methacrylate microspheres (particle size: 6.5 to 10.5 μ) sold under the trade name GANZPEARL GMP 0800 by Ganz Chemical; microspheres made from ethylene glycol dimethacrylate/lauryl methacrylate copolymer (size: 6.5 to 10.5 μ) sold under the trade name GANZPEARL GMP 0820 by Ganz Chemical or MICROSPONGE 5640 by Amcol Health & Beauty Solutions; powdered ethylene-acrylate copolymers, such as those marketed under the trade name FLOBEADS by Sumitomo Seika Chemicals; expanded powders as hollow microspheres and, in particular, microspheres formed from a polyvinylidene/acrylonitrile/methacrylate terpolymer and marketed under the trade name EXPANCEL by Kemanord Plast under references 551 DE 12 (particle size of about 12 μm and density 40 kg/m3), 551 DE 20 (particle size of approximately 30 μm and density 65 kg/m3), 551 DE 50 (particle size of approximately 40 μm) or the microspheres sold under the trade name MICROPEARL F 80 ED by Matsumoto ; powdered natural organic materials, such as powdered starches, in particular, powdered starches, in particular, corn, wheat or rice starch, optionally cross-linked, such as powdered starches cross-linked by octenylsuccinate anhydride, marketed under the trade name DRY- FLO by National Starch; silicone resin microspheres such as those sold under the trade name TOSPEARL by Toshiba Silicone, in particular TOSPEARL 240; powdered amino acids such as powdered Lauroilysin sold under the trade name AMIHOPE LL-11 by Ajinomoto; wax microdispersion particles, which preferably have dimensions smaller than 1 μm and, in particular, which vary from 0.02 μm to 1 μm, and which are substantially comprised of a wax or a mixture of waxes, such as products marketed under the trade name of Aquacer by Byk Cera and in particular: Aquacer 520 (mixture of natural and synthetic waxes), Aquacer 514 or 513 (polyethylene wax), Aquacer 511 (polymer wax) or as the products marketed under the trade name of Jonwax 120 by Johnson Polymer (mixture of polyethylene and paraffin waxes) and under the trade name Ceraflour 961 by Byk Cera (micronized modified polyethylene wax); and mixtures thereof.

HYDROPHILIC THICKENERS

[188] According to an advantageous embodiment, composition A and/or B (or the ready-to-use composition) may further comprise at least one thickener. This thickener is preferably soluble or dispersible in water.

[189] Thickeners can be of natural or synthetic origin, mineral or organic.

[190] The thickeners will preferably be anionic, zwitterionic or non-ionic polymers, associative or not.

[191] Thickeners can be chosen from cellulose derivatives such as hydroxyethylcellulose; polysaccharides and in particular gums such as xanthan gum, sclerotium gum.

[192] Associative polyurethanes are non-ionic sequenced copolymers that comprise in the chain both hydrophilic sequences generally polyoxyethylenelated in nature (polyurethanes can then be called polyether polyurethanes) and hydrophobic sequences that can be isolated aliphatic and/or cycloaliphatic chains and/or or aromatic.

[193] In particular, these polymers comprise at least two lipophilic hydrocarbon chains, which have 6 to 30 carbon atoms, separated by a hydrophilic sequence, the hydrocarbon chains can be pendant chains or chains with a hydrophilic sequence end. In particular, one or a plurality of pendant chains may be predicted. Furthermore, the polymer may comprise a hydrocarbon chain at one end or both ends of a hydrophilic sequence.

[194] Associative polyurethanes can be sequenced in the form of triblocks or multiblocks. The hydrophobic sequences can therefore be at each end of the chain (for example, triblock copolymer having a hydrophilic central sequence) or distributed both at the end and in the chain (multisequenced copolymer, for example). These polymers can also be grafted or star polymers. Preferably, associative polyurethanes are triblock copolymers, the hydrophilic sequence of which is a polyoxyethylene chain comprising 50 to 1000 oxyethylene groups. Associative polyurethanes, in general, comprise a urethane bond between hydrophilic sequences, hence the name.

[195] According to one embodiment, a non-ionic associative polymer of the polyurethane type is used as a gelling agent.

[196] As examples of non-ionic polyether polyurethanes with a grease chain that can be used in the invention, Rheolate® FX 1100 or Rheoluxe® 811 (Steareth-100/PEG-136/HDI (hexamethyl diisocyanate) copolymer) can also be used. ), Rheolate® 205 with urea function sold by ELEMENTIS or Rheolates® 208, 204 or 212, as well as Acrysol RM 184® or Acrysol RM 2020.

[197] One can also mention the product ELFACOS T210® with C12-C14 alkyl chain and the product ELFACOS T212® with C16-18 alkyl chain (PPG-14 Palmet-60 Hexyl Dicarbamate) from AKZO.

[198] The product DW 1206B® from ROHM & HAAS with C20 alkyl chain and bonded urethane, proposed at 20% dry material in water, can also be used.

[199] Solutions or dispersions of these polymers can also be used, in particular, in water or in a hydroalcoholic medium. As an example of these polymers, one can mention RHEOLATE® 255, RHEOLATE® 278 and RHEOLATE® 244 sold by ELEMENTIS. The DW 1206F product and the DW 1206J product proposed by the company ROHM & HAAS can also be used.

[200] The associative polyurethanes that can be used according to the invention are, in particular, those described in the article by Fonnum, J. Bakke and Fk. Hansen - Colloid Polym. Sci 271, 380,389 (1993).

[201] An associative polyurethane suitable for obtaining by means of polycondensation of at least three compounds comprising (i) at least one polyethylene glycol comprising 150 to 180 mol of ethylene oxide, (ii) stearyl alcohol or decyl alcohol and (iii) at least one diisocyanate.

[202] These polyether polyurethanes are sold, in particular, by ROHM & HAAS under the names ACULYN 46® and ACULYN 44® (ACULYN 46® is a polycondensate of polyethylene glycol in 150 or 180 mol of ethylene oxide, stearyl alcohol and bis methylene (4-cyclohexyl isocyanate) (SMDI), 15% by weight, in a matrix of maltodextrin (4%) and water (81%); ACULYN 44® is a polyethylene glycol polycondensate in 150 or 180 mol oxide of ethylene, decyl alcohol and methylene bis(4-cyclohexylisocyanate) (SMDI), 35% by weight, in a mixture of propylene glycol (39%) and water (26%)).

[203] Solutions or dispersions of these polymers can also be used, in particular, in water or in a hydroalcoholic medium. As an example, of these polymers we can mention RHEOLATE FX1010®, RHEOLATE FX1035® and RHEOLATE 1070® from ELEMENTIS, RHEOLATE 255®, RHEOLATE 278® and RHEOLATE 244® sold by ELEMENTIS. It is also possible to use the products ACULYN 44, ACULYN 46®, DW 1206F® and DW 1206J®, as well as Acrysol RM 184 from ROHM & HAAS or BORCHI GEL LW 44® from BORCHERS, and mixtures thereof.

[204] Preferably, a non-ionic associative polyether polyurethane is used such as that sold, in particular, by ELEMENTIS under the trade name RHEOLATE FX 1100® or RHEOLUXE 811® which is a polycondensate of polyethylene glycol in 136 mol of ethylene oxide, of polyoxyethylene stearyl alcohol in 100 mol of ethylene oxide and hexamethylene diisocyanate (IDH) which have a weight average molecular weight of 30,000 (INCI name: Steareth-100/PEG-136/HDI Copolymer).

[205] Thickeners are generally present in composition A and/or B (or in the ready-to-use composition) at a level in the range of 0% to 20% by weight, preferably 0% to 10% by weight, and with most preferably 0% to 7%, by weight, in relation to the total weight of the composition.

LIPOPHILIC THICKENERS

[206] By way of example, of a mineral lipophilic gelling agent, optionally modified clays may be mentioned, such as hectorite modified by C10 to C22 ammonium chloride, such as hectorite modified with distearyl dimethyl ammonium chloride, such as, for example, that sold under the name Bentone 38V® by ELEMENTIS.

[207] Fumed silica may also be mentioned, optionally with a hydrophobic surface treatment in which the particle size is less than 1 μm. In fact, it is possible to chemically modify the silica surface, through a chemical reaction that results in a reduction in the silanol groups present on the silica surface. The silanol groups can particularly be replaced by hydrophobic groups: hydrophobic silica is thus obtained. The hydrophobic groups may be trimethylsiloxyl groups, particularly obtained by treating fumed silica in the presence of hexamethyldisilazane. Silicas treated in this way are referred to as “silica silylate” according to the CTFA (8th edition, 2000). They are, for example, sold under the references Aerosil R812® by DEGUSSA, CAB-O-SIL TS-530® by CABOT, dimethylsilyloxyl or polydimethylsiloxane groups, particularly obtained by treating fumed silica in the presence of polydimethylsiloxane or dimethyldichlorosilane. Silicas treated in this way are referred to as “silica dimethyl silylate” according to the CTFA (8th edition, 2000). For example, they are sold under the trade name under the reference Aerosil R972® and Aerosil R974® by DEGUSSA, CAB-O-SIL TS-610® and CAB-O-SIL TS-720® by CABOT.

[208] Hydrophobic fumed silica particularly has a particle size that can be nanometer or micrometer, for example, ranging from approximately 5 to 200 nm.

[209] Polymeric organic lipophilic gelling agents are, for example, partially or fully cross-linked elastomeric organopolysiloxanes with a three-dimensional structure, such as those sold under the names KSG6®, KSG16® and KSG18® by SHIN-ETSU, Trefil E-505C® and Drawing wire E-506C® by DOW-CORNING, Gransil SR-CYC®, SR DMF10®, SR-DC556®, SR 5CYC gel®, SR DMF 10 gel® and SR DC 556 gel® by GRANT INDUSTRIES, SF 1204® and JK 113® by GENERAL ELECTRIC; ethyl cellulose such as that sold under the brand name Ethocel® by DOW CHEMICAL; galactomannans containing from one to six and, in particular, from two to four hydroxyl groups per ose, substituted by a saturated or unsaturated alkyl chain, such as guar gum alkylated with C1 to C6, and C1 to C3 alkyl chains, in particular, and mixtures the same. Block copolymers of the “diblock”, “triblock” or “radial” type, of the polystyrene/polyisoprene or polystyrene/polybutadiene type, such as those sold under the trade name Luvitol HSB® by BASF, of the polystyrene/copoly(ethylene-propylene) type ), such as those marketed under the trade name Kraton® by SHELL CHEMICAL CO or the polystyrene/copoly(ethylene-butylene) type, mixtures of triblock and radial (star) copolymers in isododecane, such as those marketed by PENRECO under the trade name Versagel®, for example, the mixture of butylene/ethylene/styrene triblock copolymer and ethylene/propylene/styrene star copolymer in isododecane (Versagel M 5960).

[210] As a lipophilic gelling agent, one can also mention polymers of average molar mass, by weight, less than 100,000, which comprise a) a polymeric skeleton having hydrocarbon repeating units provided with at least one heteroatom and, optionally , b) at least one pendant fatty chain and/or at least one terminal fatty chain that can be functionalized, which has from 6 to 120 carbon atoms and which is linked to these hydrocarbon patterns, such as those described in WO-A applications -02/056847, WO-A-02/47619, in particular polyamide resins (in particular, comprising alkyl groups having from 12 to 22 carbon atoms) such as those described in patent US-A-5783657.

[211] Among lipophilic gelling agents suitable for use, one may also mention dextrin and fatty acid esters such as dextrin palmitates, particularly such as those sold under the names Rheopearl TL® or Rheopearl KL® by CHIBA FLOUR.

[212] Polyorganosiloxane of the silicone polyamide type can also be used, such as those described in patent documents US A-5,874,069, US A-5,919,441, US A-6,051,216 and US A-5,981,680.

[213] These silicone polyamides may belong to the following two families: - polyorganosiloxanes comprising at least two amide groups capable of establishing hydrogen interactions, with these two groups being located in the polymer chain, and/or - polyorganosiloxanes comprising at least least two amide groups capable of establishing hydrogen interactions, with these two groups being located in grafts or branches.

SUSPENSION AGENTS

[214] Compositions A and/or B (or the ready-to-use composition or the single anhydrous composition), in addition, may comprise at least one or more suspending agents and/or one or more gelling agents. Some of them can perform both functions at the same time.

[215] Among the agents that can be used as a suspending agent and/or as a lipophilic gelling agent, clays can be mentioned, in the form of a powder or in the form of an oily gel; said clays capable of being optionally modified, in particular, montmorillonite clays modified such as bentonites or hydrophobic hectorites modified such as hectorites modified by a C10 to C22 ammonium chloride, such as hectorite modified with dimethyl distearyl ammonium chloride as, for example, the product Disteardimonium Hectorite (CTFA name) (reaction product of hectorite and disteardimonium chloride) sold as Bentone 38 or Bentone Gel by Elementis Specialties. One can mention, for example, the product Stearalkonium Bentonite (name CTFA) (reaction product of bentonite and quaternary ammonium stearalkonium chloride) as the commercial product sold under the name TIXOGEL MP 250® by Sud Chemie Rheologicals, United Catalysts Inc .

[216] Use may also be made of hydrotalcites, in particular, modified hydrophobic hydrotalcites such as, for example, the products sold under the name Gilugel by BK Giulini.

[217] Fumed silica may also be mentioned, optionally with a hydrophobic surface treatment in which the particle size is less than 1 μm. In fact, it is possible to chemically modify the silica surface, through a chemical reaction that results in a reduction in the silanol groups present on the silica surface. The silanol groups can particularly be replaced by hydrophobic groups: hydrophobic silica is thus obtained. The hydrophobic groups may be trimethylsiloxyl groups, particularly obtained by treating fumed silica in the presence of hexamethyldisilazane. Silicas treated in this way are referred to as “silica silylate” according to the CTFA (8th edition, 2000). They are, for example, sold under the references Aerosil R812® by DEGUSSA, CAB-O-SIL TS-530® by CABOT, dimethylsilyloxyl or polydimethylsiloxane groups, particularly obtained by treating fumed silica in the presence of polydimethylsiloxane or dimethyldichlorosilane. Silicas treated in this way are referred to as “silica dimethyl silylate” according to the CTFA (8th edition, 2000). For example, they are sold under the trade name under the reference Aerosil R972® and Aerosil R974® by DEGUSSA, CAB-O-SIL TS-610® and CAB-O-SIL TS-720® by CABOT.

[218] Hydrophobic fumed silica particularly has a particle size that can be nanometer or micrometer, for example, ranging from approximately 5 to 200 nm.

[219] According to a particular form of the invention, suspending agents or gelling agents can be activated by oils, such as propylene carbonate, triethylcitrate.

[220] The amounts of these different constituents that may be present in composition A and/or B (or in the ready-to-use composition or in the single anhydrous composition) are those conventionally used in compositions for treating perspiration.

[221] Suspending agents are preferably present in amounts ranging from 0.1% to 5% by weight, and more preferably from 0.2 to 2% by weight, relative to the total weight of the composition.

[222] The amounts of these different constituents that may be present in cosmetic compositions A and/or B (or in the ready-to-use composition or in the single anhydrous composition) are those conventionally used in compositions for treating perspiration.

AEROSOLS

[223] Compositions A and/or B can also be pressurized and packaged in an aerosol device, in particular, comprising at least one propellant.

[224] The propellant used is preferably chosen from dimethyl ether, volatile hydrocarbons such as propane, isopropane, n-butane, isobutane, n-pentane and isopentane, and mixtures thereof, optionally by at least one chlorinated and/or fluorinated hydrocarbon ; of the latter, mention may be made of the compounds sold by Dupont de Nemours under the trade names Freon® and Dymel® and, in particular, monofluorotrichloromethane, difluorodichloromethane, tetrafluorodichloroethane and 1,1-difluoroethane particularly sold under the trade name DYMEL 152 A® by DUPONT.

[225] Carbon dioxide, nitrous oxide, nitrogen or compressed air can also be used as a propellant.

[226] Preferably, the propellant is chosen from volatile hydrocarbons.

[227] More preferably, the propellant is chosen from isopropane, n-butane, isobutane, pentane and isopentane, and mixtures thereof.

[228] The weight ratio between the liquid phase and the propellant gas varies in a ratio of 5/95 to 50/50, preferably from 10/90 to 40/60, and most preferably from 15/85 to 30/ 70.

[229] According to the invention, the propellant concentration generally varies from 5 to 95%, by pressurized mass, and more preferably from 50 to 85%, by mass, in relation to the total mass of the pressurized composition A and/or B .

[230] The dispensing means, which form part of the aerosol device, generally consist of a dispensing valve controlled by a dispensing head, which in turn comprises a nozzle through which the mixture of composition A and composition B is mixed. is sprayed. The receptacle containing each pressurized composition A and B may be opaque or transparent. It can be made of glass, polymeric or metallic material, optionally coated with a layer of protective varnish.

[231] Throughout the description, including the claims, the expression “comprising one” should be understood as being synonymous with “comprising at least one”, unless otherwise mentioned.

[232] The expressions “between ... and ...” and “ranging from ... to ...” are to be understood as inclusive of limits, unless otherwise specified.

[233] In the description and Examples, unless otherwise noted, percentages are percentages by weight. The percentages are therefore expressed, in weight, in relation to the total weight of the composition. Temperature is expressed in degrees Celsius unless otherwise noted, and pressure is atmospheric pressure unless otherwise noted.

[234] The invention is illustrated in more detail by the non-limiting Examples presented from this point forward.

[235] The following examples are used to illustrate this invention. Quantities are indicated as percentages, by weight, in relation to the total weight of the composition.

EXAMPLES 1 TO 11 INFLUENCE OF THE CHOICE OF MODULATOR AGENT

[236] The following compositions are prepared by mixing ingredients of composition A on one side, and a mixture of the ingredients of composition B on the other.

[237] Next, composition B is introduced into composition A with magnetic stirring.

[238] The precipitation reaction time is measured according to the following protocol: The timer is started after mixing compositions A and B in the same volume, until a precipitate can be observed: (1) sold under the trade name CALCIUM CHLORIDE DIHYDRATE EMPROVE PH by MERCK (2) sold under the trade name ASCORBIC ACID VC 100 MESH (95%) 50 1584 2 by DSM NUTRITIONAL PRODUCTS (3) sold under the trade name of CITRIC ACID MONOHYDRATE by CITURGIA BIOCHEMICALS (4) sold under the trade name BICAR FOOD by SOLVAY

[239] The results show, as such, that the precipitation reaction between the compositions A1 and B1, on the one hand, and A2 and B1, on the other hand (therefore, with a modulating agent according to the invention), is carried out in a much slower way than between the comparative 1 compositions A and B1 (without modulating agent). (1) sold under the trade name CALCIUM CHLORIDE DIHYDRATE EMPROVE PH by MERCK (2) sold under the trade name PURAC FCC 88 by PURAC (3) sold under the trade name PROPIONIC ACID by MERCK (4) sold under the trade name of NATURAL TARTARIC ACID by INDUSTRIA CHIMICA VALENZANA (5) sold under the trade name of BICAR FOOD by SOLVAY

[240] In the same way as above, the results show that the precipitation reaction between compositions A3 and B1, or A4 and B1, or A5 and B1, or A6 and B1, or A7 and B1 (therefore, with a modulating agent according to the invention), is done much slower than between comparative 1 compositions A and B (without modulating agent). (1) sold under the trade name CALCIUM CHLORIDE DIHYDRATE EMPROVE PH by MERCK (2) sold under the trade name AQUADEW SPA-30 by AJINOMOTO (3) sold under the trade name SOKALAN CP42 by BASF (4) sold under the trade name of SOKALAN CP44 by BASF (5) sold under the trade name of BICAR FOOD by SOLVAY

[241] Again in the present application, the results show, as such, that the precipitation reaction between compositions A8 and B2, or A9 and B2, or A10 and B2 (therefore, with a modulating agent according to the invention), is done in a much slower way than between the comparative 2 compositions A and B2 (without modulating agent). (1) sold under the trade name MAGNESIUM CHLORIDE HEXAHYDRATE by DR PAUL LOHMANN (2) sold under the trade name CITRIC ACID MONOHYDRATE by CITURGIA BIOCHEMICALS (3) sold under the trade name TRISODIUM CITRATE DIHYDRATE FINE F 6000 by JUNGBUNZLAUER (4) sold under the trade name DISODIUM PHOSPHATE by BK GIULINI CHEMIE EXAMPLE 12 COMPOSITION A IN A FIRST EMULSION FORMULA

[242) Composition A12 tested comprises a base manufactured according to the method described below and containing the ingredients mentioned in the following table. The method of application of this composition is described in Example 25: (1) MAGNESIUM CHLORIDE HEXAHYDRATE by DR PAUL LOHMANN (4) sold under the trade name LANETTE D by BASF (5) sold under the trade name SIMULSOL CS ECAILLES by SEPPIC (6) sold under the trade name BELSIL DM 350 by WACKER (7) sold under the trade name 616751 HYDROLYTE-5 by SYMRISE (8) sold under the trade name SEPICIDE LD by SEPPIC

[243] Phase P1 is heated to 75°C and phase P2 is melted at 75°C. The P2 phase was slowly introduced into the P1 phase with stirring for 15 minutes. At 40°C, P3 was introduced and stirred in order to obtain good homogenization. The formula is stable for at least 24 hours. EXAMPLE 13 COMPOSITION A IN A SECOND EMULSION FORMULA

[244] Composition A13 tested comprises a base manufactured according to the method described below and containing the ingredients mentioned in the following table. The method of application of this composition is described in Example 25: (1) sold under the trade name RHEOLUXE 811 by ELEMENTIS 2 sold under the trade name MONTANOV L by SEPPIC (246) sold under the trade name BELSIL DM 350 by WACKER (247) MAGNESIUM CHLORIDE 6-HYDRATE DR PAUL LOHMANN (248) sold under the trade name CITRIC ACID MONOHYDRATE by CITURGIA BIOCHEMICALS (249) sold under the trade name TRISSODIUM CITRATE DIHYDRATE FINE F 6000 by JUNGBUNZLAUER (250) sold under the trade name SEPICIDE LD by SEPPIC (251) sold under the trade name 199602 HYDROLITE CG by SYMRISE

[245] Phase P1 is heated to 80°C. Phase P2 is heated to 80°C. Once P1 and P2 were homogenized and at 80°C, the P2 phase was slowly introduced into the P1 phase with stirring for 15 minutes. P3 was introduced and stirred to obtain good homogenization. At 40°C, phase P4 was added to the mixture with stirring until complete cooling of the fabrication (final temperature = 25°C). The formula is stable for at least 24 hours. EXAMPLE 14 COMPOSITION A IN A FIRST HYDROALCOHOLIC FORMULA

[246] Composition A14 tested comprises a base manufactured according to the method described below and containing the ingredients mentioned in the following table. The method of application of this composition is described in Example 25: (1) MAGNESIUM CHLORIDE 6-HYDRATE DR PAUL LOHMANN (2) sold under the trade name CITRIC ACID MONOHYDRATE by CITURGIA BIOCHEMICALS (3) sold under the trade name TRISODIUM CITRATE DIHYDRATE FINE F 6000 by JUNGBUNZLAUER (4) sold under the trade name SOLUBILISANT LRI by SENSIENT (5) sold under the trade name NATROSOL 250 HHR PC by ASHLAND (6) sold under the trade name DENATURED ETHANOL S96 BITREX /TERTIO by France Alcools.

[247] Phase P1 was introduced hot into the water and stirred for 30 minutes. The P2 phase was slowly introduced at 40°C into the P1 phase with stirring for 15 minutes. At 30°C, P3 was added and stirred to obtain good homogenization. The formula is stable for at least 24 hours. EXAMPLE 15 COMPOSITION A IN A SECOND HYDROALCOHOLIC FORMULA

[248] Composition A15 tested comprises a base manufactured according to the method described below and containing the ingredients mentioned in the following table. The method of application of this composition is described in Example 25: (1) MAGNESIUM CHLORIDE 6-HYDRATE DR PAUL LOHMANN (2) sold under the trade name CITRIC ACID MONOHYDRATE by CITURGIA BIOCHEMICALS (3) sold under the trade name TRISODIUM CITRATE DIHYDRATE FINE F 6000 by JUNGBUNZLAUER (4) sold under the trade name NATROSOL 250 HHR PC by ASHLAND (5) sold under the trade name BITREX/TERTIO DENATURED ETHANOL S96 sold under the trade name FRANCE ALCOOLS (6) sold under the trade name EUMULGIN CO 60 by BASF

[249] Phase P1 is heated to 50°C. Phase P2 is added with stirring until a homogeneous phase is obtained. The P3 phase was melted at 40°C and was added to the P1+P2 phase with stirring at 40°C. The temperature was allowed to return to room temperature with stirring and phase P4 was added. The formula is stable for at least 24 hours. EXAMPLE 16-17 COMPOSITION A AND COMPOSITION B SEPARATELY IN A REVERSE EMULSION FORMULA i) Compositions A16 and B4 tested comprise a base manufactured according to the method described below and containing the ingredients mentioned in the table below. The mode of application of these compositions is described in Example 25: (1) MAGNESIUM CHLORIDE 6-HYDRATE DR PAUL LOHMANN (2) sold under the trade name CITRIC ACID MONOHYDRATE by CITURGIA BIOCHEMICALS (3) sold under the trade name TRISODIUM CITRATE DIHYDRATE FINE F 6000 by JUNGBUNZLAUER (4) sold under the trade name of DIPOTASSIUM HYDROGEN DIPHOSPHATE ANHYDRO EMPROVE EXP PH EUR, BP,E340 by MERCK (5) sold under the trade name SEPICIDE LD by SEPPIC (6) sold under the trade name CITHROL DPHS-SO-(MV) by CRODA (7) sold under the trade name CETIOL CC by BASF (8) sold under the trade name ISOPROPIL PALMITATE/MB by BASF (9) sold under the trade name INTELIMER IPA 13-1 NG POLYMER by EVONIK (AIR PRODUCTS ) (10) sold under the trade name DOW CORNING 5200 FORMULATION AID by DOW CORNING

[250] For each composition A16 and B4 the protocol is as follows.

[251] The P1 phase is homogenized at room temperature. Phase B is heated to 60°C. Once P1 and P2 were homogenized, the P1 phase was slowly introduced into the P2 phase with stirring for 10 minutes. Each formula is stable for at least 24 hours: ii) Compositions A16 described in i) above were also tested with compositions B4-2, B4-3 or B4-4 below. The manufacturing method is described below, and the mode of application of these compositions is described in Example 25: (1) sold under the trade name DISODIUM PHOSPHATE by BK GIULINI CHEMIE (2) sold under the trade name EXTRA LIGHT MAGNESIUM OXIDE by DR. PAUL LOHMANN (3) sold under the trade name MAGNESIUM HYDROXIDE by DR. PAUL LOHMANN (4) sold under the trade name ISOPROPYL PALMITATE/MB by BASF (5) sold under the trade name CITHROL DPHS-SO-(MV) by CRODA

[252] For each composition A16 and B4-2, B4-3 and B4-4, the protocol is as follows: Phase P1 is homogenized at room temperature. Phase B is heated to 60°C. Once P1 and P2 were homogenized, the P1 phase was slowly introduced into the P2 phase with stirring for 10 minutes. P3 is then introduced with stirring for 10 minutes. Each formula is stable for at least 24 hours. EXAMPLE 18 ANHYDRO AEROSOL FORMULA

[253] The tested formula comprises a base manufactured according to the method described below and containing the ingredients mentioned in the following table: (1) sold under the trade name Isopropyl Palmitate by Cognis (BASF) (2) sold under the trade name Isododecane by Ineos (3) sold under the trade name HUILE DE COPRAH RAFFINEE GV 24/26 by Sio (ADM ) (4) sold under the trade name Bentone 38VCG by Elementis (5) sold under the trade name Jeffsol propylene carbonate by Huntsman (6) MAGNESIUM CHLORIDE 6-HYDRATE DR PAUL LOHMANN (7) sold under the trade name CITRIC ACID ANHYDRO by CARGILL (8) sold under the trade name TRISODIUM CITRATE DIHYDRATE FINE F 6000 by JUNGBUNZLAUER (9) sold under the trade name DIPOTASSIUM DIPHOSPHATE HYDROGEN ANHYDRO EMPROVE EXP PH EUR, BP, E340 by MERCK.

[254] Phase P1 was mixed with stirring. The P2 phase was slowly introduced into the P1 phase, then allowed to swell for five minutes. P3 was introduced. This was vigorously stirred until good homogenization was achieved. Then, phase P4 was added little by little until Petition 870220069975, of 05/08/2022, p. 79/97 homogenization. The formula is stable for at least 24 hours. EXAMPLES 19 TO 24 COMPOSITION A AND COMPOSITION B SEPARATELY IN AQUEOUS GEL FORMULA

[255] Compositions A19, A20 and B5, B6, B7, B8 tested comprise a base manufactured according to the method described below and containing the ingredients mentioned in the following table. The mode of application of these compositions is described in Example 25: (1) sold under the trade name AMIGEL GRANULE by ALBAN MULLER (2) sold under the trade name NATROSOL 250 HHR PC by ASHLAND (3) MAGNESIUM CHLORIDE 6-HYDRATE DR PAUL LOHMANN (4) sold under the trade name CITRIC ACID MONOHYDRATE by CITURGIA BIOCHEMICALS (5) sold under the trade name TRISODIUM CITRATE DIHYDRATE FINE F 6000 by JUNGBUNZLAUER (6) sold under the trade name DIPOTASSIUM DIPHOSPHATE ANHYDROGEN HYDROGEN EMPROVE EXP PH ER, BP, E340 by MERCK (7 ) sold under the trade name SEPICIDE LD by SEPPIC (8) sold under the trade name DISODIUM PHOSPHATE by BK GIULINI CHEMIE.

[256] For each composition A19, A20 and B5, B6, B7, B8, the protocol is as follows: Phase P2 was introduced into phase P1 with stirring. Once the mixture was homogeneous, phase P3 was added with stirring. Then, phase P4 was introduced with stirring. Formulas are stable for at least 24 hours. EXAMPLE 25 METHOD OF APPLICATION OF COMPOSITIONS A AND B ACCORDING TO THE INVENTION 1) Aqueous formulas:

[257] Each aqueous composition A1 to A16, A19 and A20 of the above-mentioned Examples can be applied with one of the aqueous compositions B1 to B8.

[258] For this, the method of application may comprise: - mixing shortly before use of at least one composition A chosen from A1 to A16, A19 and A20, with a composition B chosen from B1 to B6, followed by applying the resulting mixture to the surface of the skin; - application to the surface of the skin, at the same time (simultaneously) or one after the other (sequentially), of at least one composition A chosen from A1 to A16, A19 and A20, and at least one composition B chosen from from B1 to B8.

[259] Composition A chosen from A1 to A16, A19 and A20, and composition B chosen from B1 to B8, may be present on two supports or on the same support. 2) Anhydrous Formula:

[260] Typically, the anhydrous composition of example 18 already contains the mixture of cation Xn+, anion Ym- and modulating agent, and is applied directly to the skin. EXAMPLE 26 ANTIPERSPIRANT CLINICAL EFFECTIVENESS

[261] Method: a gravimetric test was carried out with compositions A11 and B3 of Example 11, in order to measure their antiperspirant effectiveness, in comparison to a control formula containing water. In short, after a three-week wash-out period, thirty-four subjects were treated for 4 days, twice a day, in the underarm area with 400 μL of each composition, applied one after the other (composition A 11, then composition B3), with a light massage between the two. Twenty-four hours after the last application, the volunteers were subjected to a sauna at 38°C and 35% RH (humidity) for forty minutes, during which sweat from their armpits was collected using cotton balls that were weighed. previously and were weighed after collection. RESULTS

[262] An 8.9% reduction in the amount of sweat was observed for the group treated according to the invention, compared to the control group with a significance p < 0.017. EXAMPLE 27

[263] The following compositions are prepared by mixing ingredients of composition A on one side (i.e., compositions A11 of Example 11, A21 or A22), and a mixture of the ingredients of composition B (i.e., composition B3 of Example 11 above, or B9 to B11) on the other.

[264] Next, composition B is introduced into composition A with magnetic stirring.

[265] The precipitation reaction time is measured as described in Examples 1 to 11 above. (1) MAGNESIUM CHLORIDE HEXAHYDRATE by DR PAUL LOHMANN (2) sold under the trade name CITRIC ACID MONOHYDRATE by CITURGIA BIOCHEMICALS (3) sold under the trade name TRISODIUM CITRATE DIHYDRATE FINE F 6000 by JUNGBUNZLAUER (4) sold under the trade name of DISODIUM PHOSPHATE by BK GIULINI CHEMIE (5) sold under the trade name of DIPOTASSIUM HYDROGEN DIPHOSPHATE ANHYDRO EMPROVE EXP PH EUR, BP, E340 by MERCK.

Claims (15)

1. COSMETIC METHOD FOR THE TREATMENT OF HUMAN PERSPIRATION, and optionally body odors resulting from perspiration, characterized by comprising the use of at least one Xn+ cation of valence n, at least one Ym- anion of valence m and at least one modulating agent, in that said cation - is chosen from carbonate (CO32-), hydrogen carbonate (HCO3-), phosphate (PO43-), polyphosphates such as diphosphate P2O74-, triphosphate P3O105-, phosphonate (PO33-), hydrogen phosphate (HPO42-), sulfate (SO42- ), sulfonate (SO32-), hydrogensulfate (HSO4-), hydrogensulfonate (HSO3-) and silicate (SiO32-); and said modulating agent being chosen from monocarboxylic or polycarboxylic acids, optionally hydroxylated, in free or salted form; Ascorbic acid; polymers or copolymers of carboxylic acids in free or salted form; and polymers or copolymers of amino carboxylic acids in free or salted form. 2. METHOD, according to claim 1, characterized by the cation Xn+ of valence n, the anion Ym- of valence m and the modulating agent being formulated in an anhydrous medium within the same composition. 3. METHOD, according to claim 1, characterized in that: - the cation Xn+ of valence n is present in a composition A; - the anion Ym- of valence m being present in a composition B, the compositions A and B being different; - the modulating agent may be present in composition A and/or in composition B, or by: - the Xn+ cation of valence n being present in composition A; - the anion Ym- of valence m being present in a composition B, the compositions A and B being different; - the modulating agent is generated during the mixing between compositions A and B. 4. METHOD according to any one of claims 1 or 3, characterized in that it comprises: (i) both mixing shortly before use of at least one composition A and at least one composition B, said compositions A and B being packaged separately, followed by applying the resulting mixture to the surface of the skin; or (ii) applying to the surface of the skin, simultaneously or sequentially, at least one composition A and at least one composition B separately packaged; or (iii) applying to the surface of the skin a composition comprising on the same support at least one composition A and at least one composition B; - said composition A comprising in a cosmetically acceptable medium at least one salt of cation Xn+ of valence n, the counter-ion being separated from the anion Ym- of valence m; and - said composition B comprising in a cosmetically acceptable medium at least one salt of anion Ym- of valence m, the counter-ion being separated from the cation Xn+ of valence n. 5. METHOD, according to any one of claims - to 4, characterized in that: - the transition metal cation Xn+ is chosen from Zinc, Manganese, Titanium and Iron, and/or - the Xn+ cation is in the form of a water-soluble salt, preferably chosen from halides, sulfates and carboxylates. 6. METHOD, according to claim 5, characterized in that the Xn+ cation salt is chosen from Calcium Chloride, Magnesium Chloride, Calcium Pidolate, Calcium Aspartate, Calcium Gluconate, Calcium Glutamate, Calcium Heptagluconate, Calcium Propionate, Calcium 2- Ketogluconate, Calcium Lactate, Calcium Ascorbate, Calcium Citrate, Magnesium Acetate, Magnesium Pidolate, Magnesium Gluconate, Magnesium Glutamate, Magnesium Heptagluconate, Magnesium 2-Ketogluconate, Magnesium Lactate magnesium, Magnesium ascorbate, Magnesium citrate, Magnesium aspartate, Manganese gluconate and Magnesium sulfate, preferably because the Xn+ cation salt is chosen from Calcium chloride, Magnesium chloride, Calcium acetate and Magnesium lactate. 7. METHOD, according to any one of claims 1 to 6, characterized in that the anion Ym- is chosen from hydrogen phosphate and hydrogen carbonate. 8. METHOD, according to any one of claims 1 to 7, characterized in that the anion Ym- is in the form of a salt preferably chosen from: - alkali metal salts such as potassium or sodium, and - ammonium salts, such as alkanolamine salts which are a sodium or potassium salt. 9. METHOD according to any one of claims 1 to 8, characterized in that the anion Ym- is in the form of a salt chosen from Na2CO3, K2CO3, NaHCO3, KHCO3, Na3PO3, Na2HPO4, NaH2PO4, Na2H2P2O7, Na4P2O7, K2HPO4 , KH2PO4, K2H2P2O7, K4P2O7, Na2SO4, MgSO4, K2SO4 and preferably NaHCO3 and K2HPO4. 10. METHOD, according to any one of claims 1 to 9, characterized in that the molar ratio between the cation Xn+ and the anion Ym- varies from 10:1 to 1:10 and more preferably from 4:1 to 1:4. 11. METHOD, according to any one of claims 3 to 10, characterized in that the total concentration of cation Xn+ and anion Ym- varies from 1 to 70% by weight, and more preferably from 2 to 50% by weight, of the total weight of compositions A and B. 12. METHOD, according to any one of claims 1 to 11, characterized in that the modulating agent is chosen from the Xn+ cation complexing agents, preferably by the modulating agent is chosen from: - propionic acid, citric acid, tartaric acid, lactic acid, malic acid, succinic acid, glutaric acid, itaconic acid, - ascorbic acid, - polymers or copolymers of carboxylic acids in free or salified form, and - polyaspartic acid; polyglutamic acid. 13. METHOD, according to claim 1, characterized in that the modulating agent is chosen from optionally hydroxylated monocarboxylic or polycarboxylic acids in free or salified form, ascorbic acid, polymers or copolymers of amino carboxylic acids in free or salified form such as polyaspartic acid , or polymers or copolymers of carboxylic acids in free or salted form, or in which the modulating agent is chosen from citric acid, ascorbic acid, lactic acid, propionic acid, tartaric acid or polyaspartic acid, in free or salted form, or polymers or copolymers of carboxylic acids. 14. METHOD, according to any one of claims 3 to 13, characterized in that composition A comprises the cation Xn+ and composition B comprises the anion Ym- are packaged separately and applied simultaneously or sequentially to the surface of the skin with a varying time interval from 1 second to 24 hours, more preferably from 10 seconds to 24 hours and even more preferably from 1 minute to 1 hour. 15. COSMETIC COMPOSITION, in particular for the treatment of human perspiration and, optionally, body odors resulting from perspiration, ready for use, characterized by including in a cosmetically acceptable medium, at least one Xn+ cation salt of valence n, at least one Ym- anion salt of valence m and at least one modulating agent, said composition comprising less than 5% by weight relative to the total weight of the aluminum salt composition, and said Xn+ cation being multivalent inorganic and chosen from of: (i) alkaline earth cations selected from Magnesium and Calcium, and (ii) transition metal cations selected from Zinc, Manganese, Titanium, Copper, Zirconium and Iron, said anion Ym- being chosen from carbonate (CO32-) , hydrogen carbonate (HCO3-), phosphate (PO43-), polyphosphates such as diphosphate P2O74-, triphosphate P3O105-, phosphonate (PO33-), hydrogen phosphate (HPO42-), sulfate (SO42-), sulfonate (SO32-), hydrogen sulfate (HSO4 -), hydrogensulfonate (HSO3-) and silicate (SiO32-); and said modulating agent being chosen from monocarboxylic or polycarboxylic acids, optionally hydroxylated, in free or salted form; Ascorbic acid; polymers or copolymers of carboxylic acids in free or salted form; and polymers or copolymers of amino carboxylic acids in free or salted form.